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ABSTRACT 
 
 
cJun NH2-terminal kinase (JNK) is a member of the MAPK (mitogen-
activated protein kinase) signaling family that responds to various 
extracellular stimuli, such as stress, growth factors, cytokines, or UV 
radiation. JNK activation can lead to cellular responses including gene 
expression, growth, survival, and apoptosis. JNK has been implicated in 
normal developmental processes, including tissue morphogenesis, as well as 
pathological processes, such as cellular transformation and cancer. JNK 
exists in three isoforms, and knockout mice have been generated for each 
isoform; the ubiquitously expressed Jnk1 and Jnk2 have been studied 
independently, however, the two isoforms are partially functionally redundant. 
Jnk1-/- Jnk2-/- mice are nonviable, therefore studies of compound JNK-
deficiency have been limited to mouse embryonic fibroblasts (MEF). 
Understanding the role of JNK in epithelial cells is now possible with the 
creation of conditional JNK knockout animals. 
I sought to elucidate the role of JNK in cellular transformation, cancer, 
and normal development. I employed both in vitro and in vivo approaches. 
First, I evaluated the role of JNK in cellular transformation using p53-/- Jnk1-/- 
Jnk2-/- MEF transduced with oncogenic Ras. To extend this study, I examined 
JNK-deficiency in a Kras-induced model of lung tumorigenesis. Second, I 
investigated JNK1- and JNK2-deficiency in a p53-mediated model of 
mammary tumorigenesis. Finally, I examined the role of JNK in mouse 
 vi
mammary gland development by establishing JNK-deficient primary mouse 
mammary epithelial cells and evaluating JNK-deficient mammary gland 
transplants. Taken together, this work provides evidence of context-
dependent roles for JNK in both normal and pathological cell biology. 
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CHAPTER I 
 
INTRODUCTION 
 
 
Mitogen-Activated Protein Kinases  
cJun NH2-terminal kinase (JNK) is a member of the mitogen-activated protein 
kinase (MAPK) signaling family. MAPK cascades are activated in response to 
various extracellular stimuli, such as stress, growth factors, cytokines, or UV 
radiation and can lead to cellular responses including gene expression, 
growth, survival, and apoptosis. The cascade consists of the upstream MAP 
kinase kinase kinase (MAPKKK) which phosphorylates the MAP kinase 
kinase (MAPKK), which in turn activates the MAPK (Figure 1). In the case of 
JNK, there are a variety of MAPKKK that can lead to activation of two MAPKK 
isoforms, MKK4 and MKK7, and these MAPKK ultimately result in activation 
of JNK. Specifically, MAPKKKs for the JNK pathway include the mixed 
lineage kinase group (MLK1-3, DLK, LZK), the MEKK group (MEKK1-4), the 
ASK group (ASK1 and 2) and TAK1 and TPL2 (Davis 2000). Activated JNK 
ultimately interacts with various substrates to alter cellular responses. A major 
substrate is cJun, a component of the AP-1 transcription factor. 
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Figure I.1 The MAPK signaling pathway. 
The MAPK signaling pathway conveys a variety of external signals that lead 
to cellular responses including growth, apoptosis, inflammation, and gene 
transcription. The signaling module consists of MAPKKKs that activate 
MAPKKs, which in turn activate MAPKs. Three major MAPK families exist: 
ERK, JNK and p38. The MAPKK isoforms MKK4 and 7 specifically activate 
JNK, while several upstream MAPKKKs activate the MKK4 and 7.  
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JNK Structure and Function 
JNK exists in three isoforms, JNK1, 2 and 3. While JNK1 and 2 are 
ubiquitously expressed, JNK3 is restricted to brain, heart and testis. All 
isoforms consist of eleven domains; the activation loop is located between 
domains seven and eight, and contains the Thr-Pro-Tyr motif that is 
phosphorylated by MKK4/7 (Derijard et al., 1994). Once activated, JNK 
phosphorylates its substrates on serine and threonine residues. JNK interacts 
with its substrates through docking motifs: the common docking site (termed 
CD domain) within JNK binds to a JNK binding domain (JBD) located within 
the substrate (Tanoue et al., 2000). This interaction provides signal 
specificity, though it is not the only mechanism. In addition to cJun, JNK 
substrates include other AP-1 transcription factor proteins JunB, JunD and 
ATF2. Beyond transcription factors, JNK can phosphorylate both pro- and 
anti-apoptotic members of the Bcl2-related protein family.  
Knockout mice of each JNK isoform have been made, and all are 
viable. Mice lacking Jnk1 or Jnk2 exhibit defects in immune responses (Dong 
et al., 1998, 2000; Sabapathy et al., 1999) while mice deficient in Jnk3 show 
protection against excitotoxic cell death (Yang et al., 1997). In vitro, mouse 
embryo fibroblasts (MEF) derived from Jnk1-null mice show reduced growth 
and a decrease in cJun expression, whereas Jnk2-null MEF proliferate rapidly 
and have increased cJun expression (Tournier et al., 2000; Sabapathy et al., 
2004). However, both JNK1 and JNK2 are positive regulators of cJun and 
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share redundant roles in its activation and expression (Jaeschke et al., 2006). 
In the absence of Jnk2, MEF exhibit a compensatory increase in JNK1 
function, accounting for the observed increase in growth and cJun expression 
(Jaeschke et al., 2006). Because combined JNK-deficiency (Jnk1-/-Jnk2-/-) is 
embryonic lethal, studies of compound JNK-deficiency have been limited to in 
vitro approaches. Again using MEF, it has been determined that lack of JNK 
expression results in decreased proliferation, similar to cJun-/- MEF, as well 
as resistance to UV-mediated apoptotic cell death (Tournier et al., 2000), 
indicating roles for JNK in growth and survival.  
In order to study the effects of JNK-deficiency in additional cell types, 
as well as the whole animal, conditional Jnk1f/f mice have been made and 
crossed with Jnk2-/- mice (Das et al., 2007). Initial examination of Jnk1f/f Jnk2-/- 
MEF following Cre-mediated excision of Jnk1 has shown that JNK-deficiency 
leads to a delayed decrease in proliferation mediated by p53-induced 
senescence, and that JNK therefore functions to suppress p53-induced 
senescence (Das et al., 2007). Crossing Jnk1f/f Jnk2-/- mice with various 
constitutive or inducible Cre-expressing transgenic animals results in tissue-
specific knockout mice. For example, Jnk1f/f Jnk2-/- mice have been crossed 
with Mx1-Cre mice, which inducibly express Cre-recombinase (Das et al, 
2009). Only recently has it been possible to achieve compound JNK-
deficiency using Cre-expressing systems, providing a powerful approach to 
understanding JNK function beyond MEF studies. 
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JNK and Development 
Beyond its role in cell growth and apoptosis, JNK is important for coordinated 
cell movement and cell rearrangement, processes essential for embryonic 
development. In Drosophila melanogaster, JNK is critical for actin-based cell 
motility that is required for the process of dorsal closure (Xia et al., 2004).  In 
Xenopus laevis oocytes, JNK was shown to regulate convergent extension 
movements through the non-canonical Wnt/planar cell polarity pathway 
(Yamanaka et al., 2002). Using cells in culture, Huang et al (2003) were able 
to demonstrate that JNK regulates migration through phosphorylation of 
paxillin, an adaptor protein that binds focal adhesion kinase (FAK). In the 
mouse, compound Jnk1-/- Jnk2-/- results in exencephaly and regional 
apoptotic defects: increased apoptosis in the forebrain and decreased 
apoptosis in the hindbrain (Sabapathy et al., 1999; Kuan et al., 1999). 
Furthermore, lack of Jnk1 and loss of one allele of Jnk2 (Jnk1-/- Jnk2+/- ) 
results in developmental defects including optic fissure closure and eyelid 
closure (Weston et al., 2003). Specifically, mice have open eyelids at birth 
(EOB), a phenotype that is also evident in Mekk1-/- mice and represents a 
defect in collective epithelial cell migration (Zhang et al., 2003). In addition, 
JNK-deficient mice show immaturity of the skin, intestinal mucosa, and lung 
epithelium (Weston et al., 2004), demonstrating its importance in epidermal 
morphogenesis. 
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JNK and Mammary Development  
Mammary gland branching morphogenesis represents a developmental 
program that requires cell growth, coordinated cell movement, and cell 
rearrangement. In the embryo, formation of ventral bilateral epidermal ridges 
(at mid-gestation) marks the beginning of mammary gland development in the 
mouse. Five paired placodes form along these lines and begin to invaginate, 
forming buds that will eventually create the mammary ductal network 
internally and the nipple externally. The surrounding stroma, a cluster of 
preadipocytes, will go on to become the mammary fat pad (Sternlicht 2005). 
Signaling between the stroma and the mammary epithelial cells drives 
branching morphogenesis. 
As gestation proceeds, a rudimentary ductal structure forms which is 
present at birth. This structure remains quiescent, growing allometrically, until 
the onset of puberty at approximately six weeks of age. Ovarian hormones, 
along with pituitary-derived growth hormone (GH), stimulate the ducts to grow 
and bifurcate (Figure I.2, Aa). GH induces expression of insulin-like growth 
factor 1 (IGF-1) and estrogen receptor alpha (ER), which in turn contribute 
to survival and proliferation. Specialized structures at the distal ends of the 
branches, termed terminal end buds (TEBs), are the site of penetration and 
growth of the nascent ducts (Hennighausen and Robinson 2001). Bifurcation 
of the TEBs results in new primary duct formation, and secondary branches 
grow laterally from the mature ducts, filling out the mammary ductal network 
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until the limits of the fat pad are reached (Figure I.2 Ab) (Sternlicht 2006).  
Tertiary branches develop with cyclic ovarian stimulation and are the sites of 
alveolar development during pregnancy. Mammary ductal development is 
complete by 10 to 12 weeks of age. Differentiation of the gland occurs during 
pregnancy and lactation, with the formation of milk-producing alveoli (Figure 
I.2, Ac-d). Upon weaning, the gland undergoes a remodeling process termed 
involution, characterized by the collapse of alveoli, the reemergence of 
adipocytes, and finally the return of the gland to its pre-pregnant state.  
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Figure I.2 Mouse mammary gland development. 
Mouse mammary gland development occurs primarily in the adult animal. Aa: 
At puberty, stimulation from ovarian hormones prompts the rudimentary gland 
to elongate and bifurcate to establish a ramified ductal structure. Penetration 
of the duct epithelium into the surrounding stroma (termed the mammary fat 
pad) is accomplished through specialized structures at the distal ends of the 
gland termed TEBs (terminal end buds). Ab: Growth into the fat pad proceeds 
until the limits are reached, approximately 10 to 12 weeks of age. Ac and Ad: 
When pregnancy occurs, the gland undergoes differentiation to form milk-
producing alveoli for lactation. Ba-Bd: Pictured are representative whole 
mounts of each stage of development. A whole mount is prepared by excising 
the entire gland, then fixing and staining it to evaluate morphology.  
 
Image taken from: 
Hennighausen, L., and Robinson, G.W. (2005) Information networks in the 
mammary gland. Nature Reviews Molecular Cell Biology 6, 715-725. 
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During mammary morphogenesis, the terminal end bud is the key 
developmental structure responsible for glandular elongation and ramification 
(Hinck and Silberstein, 2005). The end bud is comprised of outer cap cells 
and inner body cells (Figure I.3) and is surrounded by a stroma that consists 
of adipocytes and fibroblasts. Within the end bud, cells are actively 
proliferating, which serves to push the nascent ducts forward. Matrix 
remodeling and invasion into the fatty stroma contribute to penetration (Lu et 
al., 2006). Cell-cell adhesion within the end bud is also necessary for growth 
and maintenance of tissue integrity (Hinck and Silberstein, 2005), while cell 
surface receptors for extracellular matrix can also influence branching 
(Steffgen et al., 2002). 
Control of mammary branching morphogenesis occurs through 
endocrine, paracrine, and autocrine mechanisms (Sternlicht 2006). The 
circulating hormones estrogen and growth hormone are essential for 
mammary development (Bocchinfuso et al., 2000; Kleinberg et al., 2000). 
Growth hormone binds its receptor on stromal cells, which induces 
expression of IGF-1 as well as ER. IGF-1 binds its receptor (IGF-1R) located 
on epithelial cells, providing survival and proliferation signals (Bonnette et al., 
2001). The estrogen receptor alpha (ER) is expressed in both the epithelial 
and stromal compartments, and both are necessary for development (Mueller 
et al., 2002). Estrogen elicits some of its actions through activation of 
epidermal growth factor receptor (EGFR/ErbB1) (Coleman et al., 1988, 
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Sebastian et al., 1998). Although the EGFR has many ligands that promote 
mammary development, only amphiregulin is required (Luetteke et al., 1999). 
Amphiregulin-null mice have impaired ductal outgrowth, while mice lacking 
expression of EGF, TGF and heparin-binding EGF-like growth factor do not 
(Luetteke et al., 1999). While the EGFR is specifically expressed on stromal 
cells, amphiregulin is expressed as a membrane-bound precursor on 
epithelial cells (Sternlicht et al., 2005). It requires cleavage by the 
transmembrane metalloproteinase ADAM17 (a disintegrin and 
metalloproteinase 17), which is also expressed on epithelial cells (Sternlicht 
2005). ADAM17, in turn, is negatively regulated by TIMP3 (tissue inhibitor of 
metalloproteinases 3) (Sternlicht et al., 2005).  
Matrix metalloproteinases (MMPs) are expressed in response to EGFR 
activation and promote branching (Wiseman et al., 2003).  MMP2 and 3 are 
required for ductal elongation and side branching, respectively, while MMP14 
also promotes ductal development by cleaving and activating MMP2 
(Wiseman et al., 2003). Acting in collaboration or in parallel with EGFR 
signaling is the fibroblast growth factor (FGF) pathway. FGFR2b expression 
in mammary epithelial cells and FGF10 expression in the stroma are required 
for embryonic and adult mammary development (Lu et al., 2008). A dynamic 
interplay between stromal and epithelial signals underlies mammary gland 
development. 
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Figure I.3 The terminal end bud. 
The terminal end bud (TEB) is a specialized structure present in the 
developing mammary gland (Sternlicht 2005). It consists of two cell types, cap 
cells (which correspond to myoepithelial cells) and body cells (which 
correspond to luminal cells). The cap cells form an outer layer surrounding 
the multilayered body cells; the basement membrane is discontinuous around 
the cap cells. The TEB is invested in a stroma consisting of fibroblasts, 
adipocytes, and immune cells. The end bud represents the site of increased 
cell proliferation that propels the nascent ducts forward. It is also the site of 
stromal remodeling, an additional important component of ductal 
development. Primary branches are formed from bifucration of the TEBs, 
while secondary branches arise from the trailing ducts (arrowhead). Crosstalk 
between the stroma and the ductal epithelium is necessary for ductal growth.  
 
Image taken from: 
Sternlicht M.D. (2006) Key stages in mammary gland development: The cues 
that regulate ductal branching morphogenesis. Breast Cancer 
Research 8, 201. 
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The role of JNK in mammary gland development has derived from 
studies using cancer cell lines and primary mouse mammary epithelial cells 
induced to form acinar structures (Whyte et al., 2009). In a three-dimensional 
assay for acinus formation, JNK was found to be activated upon 
glucocorticoid treatment, a known mediator of tight junction adhesion that 
supports patency of the acinus (Murtagh et al., 2004). When JNK is inhibited, 
acini are unable to form due to the lack of proper cell polarization, formation 
of tight junctions, and lumen clearance (Murtagh et al., 2004). In another 
model of acinus formation using the cell line MCF-10A, Zhan and colleagues 
(2008) show that a Rac-JNK-cJun-Bim apoptotic pathway mediates c-Myc 
induced cell death. These studies provide some insight into the role of JNK in 
epithelial organization, proliferation, and apoptosis in the mammary gland, 
however, they are limited by their use of cell lines and use of a chemical 
inhibitor of JNK. No studies have yet directly evaluated JNK-deficiency in 
mammary development. 
 
JNK and Disease 
JNK has been implicated in several pathological processes, including 
ischemic injury, obesity-induced insulin resistance, liver injury, and cancer 
(Weston and Davis, 2007). Total body and tissue-specific knockout 
approaches have identified mechanisms for JNK actions in these disease 
processes and have indicated that loss of JNK in one tissue can have 
 16
systemic effects. A role for JNK in metabolic syndrome has been established 
from studies demonstrating that JNK is activated in both dietary and genetic 
models of obesity (Hirosumi et al., 2002). JNK has been shown to 
phosphorylate an inhibitory site on insulin-receptor substrate 1 (IRS-1), 
thereby repressing insulin receptor signaling and resulting in insulin 
resistance (Aguirre et al., 2000). Using a tissue-specific approach, mice that 
lack JNK1 expression in adipose tissue show increased insulin sensitivity 
compared to controls (Sabio et al., 2008). JNK1 modulates insulin sensitivity 
by regulating the expression of interleukin-6, an inflammatory cytokine that 
acts on the liver to induce insulin resistance (Sabio et al., 2008). The JNK 
pathway is also important for beta cell function and viability (Ammendrup et 
al., 2000). A study of Jnk1-/- and Jnk2-/- islets shows that Jnk1-deficiency in 
particular improves insulin output, increases resistance to cytokine-mediated 
apoptosis, and improves survival of grafted islets (Varona-Santos et al., 
2008).  
A role for JNK has also been demonstrated in models of liver injury. In 
a concavalin A-induced model of hepatitis, it was determined that Jnk1f/f Jnk2-
/- Mx1-Cre+ livers are protected, due to the effects of JNK-deficiency in 
resident Kupffer and NKT cells (Das et al., 2009). The JNK pathway has also 
been implicated in mouse models of acetaminophen-induced liver injury. 
Studies have demonstrated increased JNK activity in mouse livers and 
attenuation of injury with administration of JNK inhibitors (Gunawan et al., 
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2006; Henderson et al., 2007). These studies were extended to determine 
ASK1 as the upstream MAPKKK (Nakagawa et al., 2008).  
 
JNK and Cancer 
JNK has been implicated as being both pro- and anti-tumorigenic (Whitmarsh 
and Davis 2007). Evidence in support of its role as a pro-tumorigenic 
molecule comes from in vitro studies of cell transformation as well as in vivo 
models of tumor formation. Cell transformation via classic oncogenes, 
including Ras, has been shown to involve JNK signaling. In its constitutively 
active, oncogenic form, Ras is able to activate a variety of signaling pathways 
that contribute to transformation, including the JNK signaling pathway 
(Kennedy and Davis 2003). Specifically, in fibroblasts lacking cJun, a major 
JNK substrate, Ras is unable to induce transformation (Johnson et al.,1996). 
Mutation of the JNK phosphorylation sites on cJun also impairs cellular 
transformation (Behrens et al., 2000). Furthermore, mice expressing cJun 
with mutated JNK phosphorylation sites develop fewer osteosarcomas and 
skin tumors in response to oncogenic Ras (Behrens et al., 2000). In a mouse 
model of intestinal cancer based on Apc(Min) mutation, reduced tumor 
number and increased survival were observed when cJun was absent or its 
N-terminal phosphorylation was absent (Nateri et al., 2005). In a skin cancer 
model using topical application of phorbol ester, JNK2-null mice show 
reduced tumor formation (Chen et al., 2001). Human cancer cell lines 
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including lung, prostate, and glioblastoma have increased JNK2 activity, 
suggesting that JNK is needed for proliferation and tumorigenicity (Bost et al., 
1999; Potapova et al., 2000; Yang et al., 2003, Cui et al., 2006). In breast 
cancer cell lines, inhibition of JNK resulted in cell cycle arrest, reduced 
proliferation and apoptosis (Mingo-Sion et al., 2004). Clinical studies using 
biochemical and immunohistological analysis of human brain tumors, 
osteosarcomas and breast adenocarcinomas show high expression of 
phosphorylated JNK, which correlates with a worse prognosis (Antonyak et 
al., 2002; Papachristou et al., 2003; Yeh et al., 2006).  
Compelling evidence also exists to support a role of JNK in tumor 
suppression. Fibroblasts null for JNK and transformed by Ras show a small 
reduction of growth in soft agar, however, when injected intravenously into 
nude mice form many more tumors and larger tumors than wild type cells 
(Kennedy et al., 2003). In this model, the JNK-null tumors had much fewer 
apoptotic cells than did the wild type tumors, highlighting the importance of 
JNK as a mediator of apoptosis (Tournier et al., 2000) and providing a 
possible mechanism for tumor suppression. JNK-mediated apoptosis involves 
Bcl2-family proteins, which act to promote or inhibit apoptosis. 
Phosphorylation of Bim and Bmf (Lei and Davis, 2003; Hubner et al., 2008; 
Hubner et al., 2010) results in the release of pro-apoptotic Bax and Bak from 
sequestration, allowing Bax to translocate to the mitochondria where it 
promotes cytochrome c release. Another possible mechanism for JNK-
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mediated apoptosis involves phosphoryation of 14-3-3, a protein that normally 
sequesters Bax in the cytoplasm. Phosphorylation of 14-3-3 liberates Bax, 
again allowing it to mediate cytochrome c release (Tsuruta et al., 2004). 
There is also evidence that Bax is a direct target of the JNK pathway (Kim et 
al., 2006). In addition, direct phosphorylation of the anti-apoptotic members 
Bcl2, Bcl-xl and Mcl-1 serves to inhibit these proteins and therefore promote 
apoptosis (Maundrell et al., 1997; Fan et al., 2000, Inoshita et al., 2002). JNK 
has also been shown to regulate expression of TGF-1 through repressive 
actions of cJun on the TGF-1 promoter (Ventura et al., 2004). The role of 
increased TGF-1 signaling in tumor progression is well established; the 
ability of JNK to negatively regulate TGF-1 expression points to another 
mechanism whereby JNK can act as a tumor suppressor. Finally, in a mouse 
skin tumor model, JNK1-null mice show increased formation of skin tumors 
(Chen et al., 2001). The wide-ranging evidence implicating JNK in 
tumorigenesis demonstrates that JNK is indeed fundamental to basic cell 
biology. 
 
Rationale and Objectives 
Considering the importance of the JNK pathway in fundamental cellular 
processes, it is of interest to determine, on a tissue-specific level, whether 
and how JNK acts in normal development as well as tumorigenesis. While it 
has been possible to study JNK-deficient mouse embryo fibroblasts, few 
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investigations have provided insight into the role of JNK in epithelial cells. I 
sought to elucidate the role of JNK in cellular transformation, cancer, and 
normal development. I began by examining transformed JNK-null fibroblasts. 
In collaboration, I investigated JNK1- and JNK2-deficiency in a p53-mediated 
model of mammary tumorigenesis and compound JNK-deficiency in a Kras-
mediated model of lung tumor formation. Finally, I determined the role of JNK-
deficiency in mammary gland development using both in vitro and in vivo 
approaches. 
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CHAPTER II 
ROLE OF JNK IN RAS-MEDIATED TUMOR FORMATION 
 
Summary 
The cJun NH2-terminal kinase (JNK) signal transduction pathway 
causes increased gene expression mediated, in part, by members of the 
activating transcription factor protein (AP1) group.  JNK is therefore 
implicated in the regulation of cell growth and cancer.  To test the role of JNK 
in Ras-induced tumor formation, I examined the effect of compound ablation 
of the ubiquitously expressed genes Jnk1 plus Jnk2.  I report that JNK is 
required for Ras-induced transformation of p53-deficient primary cells in vitro.  
Moreover, JNK is required for lung tumor development caused by mutational 
activation of the endogenous KRas gene in vivo.  Together, these data 
establish that JNK plays a key role in Ras-induced tumorigenesis.   
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Introduction 
The cJun NH2-terminal kinase (JNK) is a member of the MAP kinase group 
that is activated by cytokines / growth factors and also by exposure to 
environmental stress (Davis, 2000).  Targets of the JNK pathway are 
represented, in part, by members of the activator protein 1 (AP1) group of 
transcription factors, including cJun, JunB, JunD, and related proteins (Davis, 
2000).  JNK can phosphorylate the NH2-terminal activation domain of these 
molecules to promote increased transcription activity (Davis, 2000).  
Moreover, JNK activation causes increased expression of Jun family proteins 
(Ventura et al., 2003).  JNK therefore acts as a major physiological regulator 
of AP1-dependent gene expression (Davis, 2000).  AP1-dependent gene 
expression is implicated in cell proliferation (Whitmarsh and Davis, 1996).  
Consequently, the JNK signal transduction pathway may increase cell 
proliferation and dysregulated JNK signaling may contribute to cancer.   
 The role of JNK in cancer has been studied using mouse models.  Two 
of the genes that encode JNK are expressed ubiquitously (Jnk1 and Jnk2) 
and a third gene (Jnk3) is primarily expressed in the nervous system (Davis, 
2000).  Studies using Jnk1-/- mice and Jnk2-/- mice have demonstrated that 
JNK can cause both positive and negative changes in tumor development 
(Davis, 2000; Weston and Davis, 2007).  Thus, Jnk1-/- mice exhibit decreased 
(and Jnk2-/- mice exhibit increased) carcinogen-induced skin cancer 
compared with wild-type mice (Chen et al., 2001; She et al., 2002).  
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Moreover, carcinogen-induced hepatocellular carcinoma (Hui et al., 2008) 
and Bcr-Abl-induced lymphoma (Hess et al., 2002) are suppressed in Jnk1-/- 
mice (but not Jnk2-/- mice).  In contrast, studies of glioblastoma, prostate 
cancer, and lung carcinoma cell lines have identified important roles for JNK2 
(but not JNK1) (Bost et al., 1999; Potapova et al., 2000; Yang et al., 2003; Cui 
et al., 2006).  Together, these data confirm that JNK may play a role in cancer 
development, but the relative roles of the JNK1 and JNK2 isoforms are 
unclear.   
 It is established that the Jnk1 and Jnk2 genes exhibit partially 
redundant functions (Tournier et al., 2000; Jaeschke et al., 2006; Das et al., 
2007; Das et al., 2009).  Studies of compound mutants with ablation of both 
ubiquitously expressed Jnk genes are therefore required.  These studies have 
been compromised by the early embryonic lethal phenotype of Jnk1-/- Jnk2-/- 
mice (Kuan et al., 1999).  Nevertheless, Jnk1-/- Jnk2-/- embryonic fibroblasts 
(MEF) have been prepared.  These cells exhibit an early senescence 
phenotype that is caused by engagement of the p53 tumor suppressor 
pathway (Tournier et al., 2000; Das et al., 2007).  However, immortalized 
wild-type and JNK-deficient fibroblasts have been isolated using the 3T3 
protocol that disrupts the p53 pathway (Kennedy et al., 2003).  Retroviral 
transduction assays with ectopic expression of activated Ras demonstrates 
that both WT and JNK-deficient 3T3 cells can exhibit properties of 
transformed cells (Kennedy et al., 2003).  This study indicates that JNK may 
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not be required for Ras-induced transformation, but this conclusion is subject 
to a number of important caveats.  Thus, it is likely that the 3T3 
immortalization protocol does not cause the same genetic alterations in both 
WT MEF and Jnk1-/- Jnk2-/- MEF.  Moreover, these studies of 3T3 cells 
expressing ectopic Ras may not be informative for understanding the 
mechanism of epithelial cell tumor formation by mutational activation of the 
endogenous KRas gene.   
 The purpose of this study was to test the requirement of JNK for Ras-
induced tumorigenesis.  First, I examined whether JNK is required for the 
Ras-induced transformation of primary MEF with a defined genetic 
background.  Second, I examined the requirement of JNK for epithelial cell 
transformation using an established model of lung cancer in mice.  I conclude 
that JNK is critically required for Ras-induced transformation of MEF in vitro 
and for Ras-induced lung tumor formation in vivo.   
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Materials and Methods 
Mice 
We have described Jnk1-/- mice (Dong et al., 1998), Jnk2-/- mice (Yang et al., 
1998), mice with conditional expression of Jnk1 (Das et al., 2007), and mice 
with conditional expression of KRasG12D (Jackson et al., 2001).  Mice with 
Trp53 gene ablation (Donehower et al., 1992) were provided by Dr. Stephen 
Jones, University of Massachusetts Medical School.  Mice with conditional 
expression of Trp53 (Marino et al., 2000) were obtained from the Jackson 
Laboratory (strains B6.129P2-Trp53tm1Brn/J (Stock # 008462).  Mice 
expressing 4-hydroxy-tamoxifen-stimulated Cre (Badea et al., 2003) were 
obtained from the Jackson Laboratory (strain B6;129-
Gt(ROSA)26Sortm1(cre/ERT)Nat/J (Stock # 004847)).  The mice used in this study 
were backcrossed to the C57BL/6J strain (Jackson Laboratories) and were 
housed in a facility accredited by the American Association for Laboratory 
Animal Care (AALAC).  The Institutional Animal Care and Use Committee 
(IACUC) of the University of Massachusetts approved all studies using 
animals.   
 
Genotype analysis 
Genotype analysis was performed by PCR using genomic DNA as the 
template.  The Jnk1LoxP (1.1kb) and Jnk1 (0.4kb) alleles were identified using 
the amplimers 5’-CCTCAGGAAGAAAGGGCTTATTTC-3’ and 5’-
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GAACCACTGTTCCAATTTCCATCC-3’. The wild-type Jnk1  (460 bp) and 
knockout Jnk1 (390 bp) alleles were identified using the amplimers 5’-
CGCCAGTCCAAAATCAAGAATC-3’, 5’-
GCCATTCTGGTAGAGGAAGTTTCTC-3’, and 5’-
CCAGCTCATTCCTCCACTCATG-3’.  The wild-type Jnk2 (400 bp) and 
knockout Jnk2 (270 bp) alleles were identified using the amplimers 5’- 
GGAGCCCGATAGTATCGAGTTACC-3’, 5’-
GTTAGACAATCCCAGAGGTTGTGTG-3’, and 5’-
CCAGCTCATTCCTCCACTCATG-3’..  The wild-type Trp53  (320 bp) and 
knockout Trp53 (150 bp) alleles were identified using the amplimers 5’-
GTGTTTCATTAGTTCCCCACCTTGAC-3’, 5’-
ATGGGAGGCTGCCAGTCCTAACCC-3’, 5’-
GTGGGAGGGACAAAAGTTCGAGGCC-3’ and 5’-
TTTACGGAGCCCTGGCGCTCGATGT-3’.  The wild-type Trp53 (288 bp) and 
Trp53LoxP (370 bp) alleles were identified using the amplimers 5’-
AGCACATAGGAGGCAGAGAC-3’ and 5’-CACAAAAACAGGTTAAACCCAG-
3’.  The Trp53 (612 bp) allele was identified using the amplimers 5’-
CACAAAAACAGGTTAAACCCAG-3’ and 5’-
GAAGACAGAAAAGGGGAGGG-3’.  The wild-type KRas  (285 bp), KRasG12D 
(315 bp), and Lox-Stop-LoxP-KRasG12D (600 bp) alleles were identified using 
the amplimers 5’-GGGTAGGTGTTGGGATAGCTG-3’ and 5’-
TCCGAATTCAGTGACTACAGATGTACAGAG-3’.  The Rosa26  (600 bp) and 
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Rosa26-CreERT (300 bp) alleles were identified using the amplimers 5’-
GCGAAGAGTTTGTCCTCAACC-3’, 5’-GGAGCGGGAGAAATGGATATG-3’, 
and 5’-AAAGTCGCTCTGAGTTGTTAT-3’.   
 
Tumor assays 
Lung tumors were studied in mice with conditional expression of KRasG12D.  
Lung-specific expression of KRasG12D was studied using calcium phosphate 
precipitated Adenovirus-Cre (Gene Transfer Vector Core, University of Iowa; 
2.5 x 107 PFU/mouse) and nasal instillation (Jackson et al., 2001).  The 
tumorigenic potential of MEF was examined by subcutaneous injection of 2 x 
105 cells in 12-week-old male C57BL/6J mice (Jackson Laboratories).  The 
mice were euthanized on day 21.   
 
Cell culture 
Primary mouse fibroblasts (embryonic day 11) were prepared and cultured in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf 
serum, 1% penicillin/streptomycin and 1% glutamine (Invitrogen).  All studies 
were performed using low-passage primary MEF (< passage 4).  Cre-
mediated gene ablation was performed by treating MEF with 1 µM 4-
hydroxytamoxifen (24 h).  Ectopic expression of HRasL61 was performed by 
retroviral transduction (Kennedy et al., 2003).  Soft agar assays were 
performed using methods described previously (Clark et al 1995).  Cell 
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number was measured using a hemocytometer and by staining with crystal 
violet (Kennedy et al., 2003).   
 
Immunoblot analysis 
Cell lysates were examined by probing with antibodies to caspase 3 (Cell 
Signaling Technology), E-cadherin (Cell Signaling Technology), JNK1/2 (BD 
Biosciences), N-cadherin (BD Biosciences), and OB-cadherin (Santa Cruz 
Biotechnology), phospho-JNK (Cell Signaling Technology), PARP (BD 
Biosciences), PCNA (Invitrogen), and -Tubulin (Sigma).  Immune complexes 
were detected using enhanced chemiluminescence (NEN). 
 
ELISA 
Multiplexed ELISA was performed using a Luminex 200 machine (Millipore).  
Cell lysates were probed using the BioPlex Phosphoprotein and Total Target 
Assay kit to measure phosphorylated and total JNK, ERK, p38 and AKT 
(BioRad).   
 
ROS assay 
Cells grown on glass-bottom dishes (MatTek) dishes were pretreated (8 hr) 
without (control), or with 1µg/mL rotenone (Sigma) or 2.5 µM 
diphenyleneiodonium chloride (DPI) (Sigma) and then incubated with 10µM 
2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) (Invitrogen) for 1 hr at 
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37°C.  The cells were washed three times with phosphate-buffered saline and 
imaged using a fluorescence microscope (Zeiss Axiovert).  Fluorescence 
intensity was measured using ImageJ software. 
 
Analysis of mRNA 
Total RNA was isolated from cell lines and real-time reverse transcription 
PCR was performed using TaqMan probes for Nox4 (Mm00479246_m1), 
p22phox (Mm00514478_m1), and Gapdh (#4352339E) (Applied Biosystems).  
The relative expression of Nox4 and p22phox mRNA was calculated by 
normalizing to the amount of Gapdh mRNA in each sample.   
 
Immunofluorescence analysis 
Cells grown on coverslips were washed with phosphate-buffered saline 
(PBS), fixed in 4% paraformaldehyde (15 min), washed with PBS, and then 
incubated in blocking buffer (0.3% Triton / PBS / 5% normal goat serum) for 1 
hr. at 25 °C.  Incubation with primary antibodies (E-cadherin (Cell Signaling 
Technology) and N-cadherin (BD Biosciences)) was performed in blocking 
buffer for 14 hr. at 4°C.  The cells were washed and incubated with secondary 
antibody (goat anti-mouse or anti-rabbit AlexaFluor-488 (Invitrogen)) in 
blocking buffer for 1 hr. at 25 °C.  The coverslips were washed in PBS and 
mounted using VectaShield medium containing DAPI (Vector Labs.).  Images 
were examined using a Leica TCS SP2 confocal microscope.   
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DNA fragmentation assays 
Genomic DNA fragmentation was measured using the Cell Death Detection 
Elisaplus kit (Roche) according to the manufacturer’s recommendations (Lamb 
et al., 2003). 
 
Analysis of tissue sections 
Histology was performed using tissue fixed in 10% formalin for 24h, 
dehydrated and embedded in paraffin.  Sections (7µm) were cut and stained 
using hematoxylin and eosin (Biocare Medical).  Immunofluorescence 
analysis was performed using de-parafinized sections treated with the 
endogenous Biotin-Blocking kit (Invitrogen), staining (4°C, 12h) with biotin-
conjugated anti-PCNA, and the incubation (25 °C, 1hr) with AlexaFluor633-
conjugated Streptavidin.  The sections on coverslips were washed, and 
mounted on slides using VectaShield medium containing DAPI (Vector 
Labs.).  Images were examined using a Leica TCS SP2 confocal microscope.   
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Results 
Role of p53 in JNK-regulated senescence and apoptosis.   
It is established that compound-deficiency of JNK1 plus JNK2 causes 
premature senescence that is associated with increased expression of p53 
(Tournier et al., 2000; Das et al., 2007).  To test whether JNK-deficiency 
causes p53-dependent senescence, I prepared wild-type (WT), Trp53-/-, and 
Jnk1-/- Jnk2-/- Trp53-/- mice (Jnk-/- Trp53-/-) murine embryo fibroblasts (MEF).  
The triple knockout Jnk-/- Trp53-/- MEF did not exhibit an early senescence 
phenotype.  These data demonstrate that JNK-deficiency causes p53-
dependent senescence in MEF.   
 Microscopic examination of exponentially growing cultures of WT, 
Trp53-/-, and Jnk-/- Trp53-/- primary MEF showed no major differences in cell 
morphology (Figure II.1A).  However, these cultures were markedly different 
when grown to high density.  The WT MEF formed a growth-arrested 
monolayer at confluence (Figure II.1A).  In contrast, the Trp53-/- MEF did not 
exhibit contact growth inhibition and formed densely packed cultures with 
multiple layers (Figure II.1A).  The Trp53-/- over-growth phenotype was 
strongly suppressed in confluent cultures of Jnk-/- Trp53-/- MEF (Figure II.1A).  
This conclusion was confirmed by measurement of cell numbers (Figure 
II.1B).  Moreover, the effect of p53-deficiency to increase cell growth in low 
serum was suppressed by JNK-deficiency (Figure II.1B).  To test the role of 
JNK in three dimensional cultures of p53-deficient MEF, I examined the 
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growth of cells in soft agar.  WT cells did not grow in soft agar, but Trp53-/- 
MEF formed small colonies (Figure II.1C and D).  JNK-deficiency suppressed 
this effect of p53-deficiency to cause growth in soft agar (Figure II.1C and D).  
Together, these data demonstrate that the effect of p53-deficiency to cause 
loss of contact growth inhibition and proliferation in soft agar requires JNK.   
 To confirm the effect of JNK-deficiency on cell morphology (Figure 
III.1A), I employed a conditional gene ablation strategy using primary MEF 
prepared from Rosa26-CreERT+/- Trp53LoxP/LoxP mice and Rosa26-CreERT+/- 
Trp53LoxP/LoxP  Jnk1LoxP/LoxP Jnk2-/- mice.  The effect of activated KRas was 
examined using MEF prepared from mice that were heterozygous for the 
LoxP-Stop-LoxP KRasG12D allele.  Cre-mediated recombination to ablate the 
floxed Trp53 / Jnk1 alleles and to express the KRasG12D allele was initiated by 
treatment of the MEF with 4-hydoxytamoxifen.  Morphological comparison of 
Trp53-/- and Trp53-/- Jnk-/- MEF expressing activated Ras demonstrated that 
JNK-deficiency prevented the high density growth of the MEF at confluence in 
multiple layers (Figure II.2A).  Together, these data demonstrate that JNK 
regulates MEF morphology.   
 Cadherins play an important role in homotypic cellular interactions 
(Cavey and Lecuit, 2009).  Expression of E-cadherin, N-cadherin, and OB-
cadherin was detected in Trp53-/- and Jnk-/- Trp53-/- MEF (Figure II.2B).  High 
levels of N-cadherin were found in Trp53-/- MEF (Figure II.2B).  In contrast, 
Jnk-/- p53-/- MEF expressed less N-cadherin and more OB-cadherin than p53-/- 
 33
MEF (Figure II.2B).  Studies using MEF with activated Ras demonstrated 
decreased N-cadherin expression by p53-/- MEF and markedly increased 
expression of E-cadherin by Jnk-/- p53-/- MEF (Figure II.2B).  
Immunofluorescence analysis confirmed that activated Ras reduced N-
cadherin expression by Trp53-/- MEF and that activated Ras increased E-
cadherin expression by Trp53-/- Jnk-/- MEF (Figure II.2C).  These changes in 
cadherin expression may contribute to the altered cell morphology of Trp53-/- 
and Jnk-/- Trp53-/- MEF (Figures II.1A and II.2A). 
 It is established that the JNK signaling pathway contributes to the 
apoptotic response to some insults by activating the intrinsic (mitochondrial) 
pathway (Tournier et al., 2000).  The mechanism is mediated, in part, by 
phosphorylation of members of the Bcl2-related protein family, including Bim, 
Bmf, and Mcl-1 (Hubner et al., 2008; Morel et al., 2009; Hubner et al., 2010).  
A role for p53 in JNK-dependent apoptosis has also been proposed (Fuchs et 
al., 1998a; Fuchs et al., 1998b; Buschmann et al., 2001).  To test the 
requirement of p53 in JNK-mediated apoptosis, I examined the effect of UV 
radiation on JNK and p53-deficient MEF (Figure II.3).  UV-stimulated genomic 
DNA fragmentation assays demonstrated that both p53-/- MEF and Jnk-/- 
Trp53-/- MEF exhibited resistance to UV radiation (Figure II.3A).  However, 
time course analysis of cell survival demonstrated that Trp53-/- MEF were 
partially resistant to UV radiation and that Jnk-/- Trp53-/- MEF exhibited 
significantly increased resistance to UV radiation (Figure II.3B).  This 
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conclusion was confirmed by the analysis of colony formation following 
exposure to UV radiation (Figure II.3C).  These data demonstrate that JNK 
can regulate apoptosis independently of p53.  To obtain biochemical evidence 
to support this conclusion, I examined UV-stimulated activation of caspase 3 
and the cleavage of the caspase substrate PARP (Figure II.3D).  I found that 
p53-deficiency did not prevent caspase 3 activation, but caspase 3 activation 
was strongly suppressed in Jnk-/- Trp53-/- MEF.  These data demonstrate that 
p53 is not required for JNK-dependent apoptosis.   
Together, these data demonstrate that p53 is an important mediator of 
senescence, but not resistance to apoptosis, caused by JNK-deficiency.  Loss 
of p53 enables the proliferation of JNK-deficient cells.  However, JNK is 
required for the loss of contact growth inhibition, and for growth in soft agar, 
caused by p53-deficiency. 
 
JNK-deficiency suppresses Ras-stimulated transformation in vitro.   
The Trp53-/- and Jnk-/- Trp53-/- MEF isolated represent genetically defined 
primary cells that can be employed to test the requirement of JNK for 
transformation by Ras in vitro (Figure II.4).  Control studies confirmed the 
presence of a functional JNK signaling pathway in Trp53-/- MEF, but not in 
Jnk-/- Trp53-/- MEF (Figure 4A).  Microscopic examination demonstrated that 
activated Ras caused p53-/- MEF to exhibit a spindle-shaped morphology, but 
this morphological change was reduced in Jnk-/- p53-/- MEF (Figure II.4B).  
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Measurement of growth in response to different concentrations of serum 
demonstrated that Ras increased the saturation density of both Trp53-/- and 
Jnk-/- Trp53-/- MEF, although the JNK-deficient MEF exhibited less growth 
(especially in low serum) compared with p53-/- MEF (Figure II.4C).  This 
conclusion was confirmed by direct measurement of cell proliferation in low 
serum (1%) and high serum (10%) concentrations (Figure II.4D and E).  
Together, these data demonstrate that JNK-deficiency does not prevent the 
effects of activated Ras on proliferation in vitro.   
 Although JNK-deficiency did not prevent Ras-stimulated growth (Figure 
II.4), I questioned whether the loss of JNK might influence other signal 
transduction pathways in MEF with activated Ras.  No significant differences 
in the activation of ERK, p38 MAP kinase, and AKT were detected when 
Trp53-/- and Jnk-/- Trp53-/- MEF were compared (Figure II.5A).  However, I 
detected reduced reactive oxygen species (ROS) were detected in Jnk-/- 
Trp53-/- MEF compared with Trp53-/- MEF (Figure II.5B).  The ROS in Trp53-/- 
MEF with activated Ras was suppressed by diphenylene iodonium chloride 
(DPI), an inhibitor of NADPH oxidases (Nox) enzymes, but not by the 
mitochondrial electron transport inhibitor rotenone (Figure II.5C).  These data 
are consistent with Nox-dependent, rather than mitochondria-dependent, 
ROS accumulation (Kamata and Hirata, 1999; Wu and Terada, 2009).  Nox1 
and Nox4 have been implicated in ROS production by MEF (Dolado et al., 
2007).  JNK-deficiency caused no change in the expression of Nox1 (data not 
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shown), but JNK-deficiency did cause reduced expression of Nox4 (Figure 
II.5D).  Expression of the Nox enzyme subunit p22phox was not altered by 
JNK-deficiency (Figure II.5D).   
 ROS production has been implicated in tumorigenesis (Suh et al., 
1999).  The greater ROS detected in Trp53-/- MEF compared with Jnk-/- Trp53-
/- MEF suggests that JNK-deficiency may alter the tumorigenic potential of 
these MEF with activated Ras.  To test this prediction, I examined the growth 
of these MEF in soft agar assays in vitro.  I found that activated Ras caused 
growth of large colonies of Trp53-/- MEF in soft agar, but activated Ras did not 
cause the growth of large Jnk-/- Trp53-/- MEF colonies in soft agar (Figure 
II.6A and B).  Similarly, subcutaneous growth of Trp53-/- MEF with activated 
Ras was observed in syngeneic mice, but this growth was strongly 
suppressed by JNK-deficiency (Figure II.6C and D).  Together, these data 
demonstrate that JNK is required for Ras-induced transformation of p53-
deficient MEF in vitro.   
JNK-deficiency suppresses Ras-induced lung tumor formation in vivo.   
In vitro studies suggest that JNK is required for Ras-stimulated transformation 
(Figure II.6).  To test whether JNK contributes to Ras-stimulated 
transformation in vivo, I examined the effect of activated Ras in an 
established model of lung tumorigenesis (Jackson et al., 2001).  Lung-specific 
expression of KRasG12D was studied using nasal instillation of Adenovirus-Cre 
(Jackson et al., 2001).  I compared the effect of endogenous Kras activation 
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in Jnk1+/+ Jnk2+/+ (Control) mice and in mice with conditional compound JNK-
deficiency (Jnk1LoxP/LoxP Jnk2-/-).  Expression of KRasG12D caused lesions in 
the lungs, including atypical adenomatous hyperplasia, epithelial hyperplasia 
of bronchioles, and adenomas (Figure II.7A and B).  Comparison of control 
mice with JNK-deficient mice demonstrated that the number of hyperplastic 
lesions and adenomas was greatly reduced in the JNK-deficient mice (Figure 
II.7C and D).  Immunofluoresence analysis of lung sections demonstrated that 
JNK-deficiency caused a marked decrease in staining for the proliferation 
marker PCNA (Figure II.7E).  No major differences in apoptosis markers 
(caspase 3 activation and PARP cleavage) between control and JNK-deficient 
lungs were detected (Figure II.7F).  Together, these data demonstrate that 
JNK is required for the efficient formation of Ras-induced lesions in the lung.    
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Discussion 
This study demonstrates that JNK can play a major role in Ras-induced tumor 
formation.  Specifically, JNK is essential for transformation of primary p53-/- 
MEF by activated Ras in vitro.  Moreover, JNK is required in a mouse model 
of Ras-induced lung tumor formation in vivo.  Together, these data provide 
strong evidence that the JNK signaling pathway may contribute to the 
development of cancer.   
 Further studies are needed to identify the signaling pathway that leads 
to Ras-induced JNK signaling.  A recent study established that Rac1 is 
required for Ras-induced lung tumor formation (Kissil et al., 2007).  Since 
Rac1 can cause JNK activation (Bagrodia et al., 1995; Coso et al., 1995; 
Minden et al., 1995), it is possible that this role of Rac1 may reflect a 
requirement of Rac1 for JNK activation in this model of Ras-induced lung 
tumorigenesis.  Targets of Rac1 that may mediate JNK pathway activation 
include members of the mixed-lineage protein kinase family (Gallo and 
Johnson, 2002).   
 Additional studies are required to identify JNK substrates that are 
relevant to lung tumorigenesis.  It is possible that AP1 family transcription 
factors, that are activated by JNK, may contribute to Ras-induced lung tumor 
formation.  However, many other targets of JNK signaling, in both the 
cytoplasm and the nucleus, may contribute to JNK-dependent tumorigenesis 
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(Weston and Davis, 2007).  Detailed analysis of these JNK substrates is 
required to identify those relevant to lung tumorigenesis.   
 
JNK prevents contact growth inhibition 
JNK may contribute to dysregulated cellular proliferation by interfering with 
contact growth inhibition.  The Trp53-/- and Trp53-/- KRasG12D primary MEF 
exhibit defects in contact growth inhibition and form multiple layers when 
grown to confluence (Figures II.1A and II.2A).  In contrast, compound 
deficiency of Jnk1 plus Jnk2 prevents the over-growth phenotype of both 
Trp53-/- and Trp53-/- KRasG12D primary MEF (Figure II.1A and II.2A).  This 
effect of JNK correlates with altered expression of the cadherin family of 
adhesion proteins (Figure 2B,C).  Strikingly, Ras-transformed Trp53-/- primary 
MEF unexpectedly express high levels of E-cadherin (Figure II.2B and C).  
The increased E-cadherin expression may contribute to increased 
intercellular adhesion.  Moreover, in the context of Ras-induced epithelial cell 
tumorigenesis, increased E-cadherin expression may decrease epithelial-
mesenchymal transition (EMT).  Indeed, it is established that EMT of lung 
epithelium is suppressed by JNK-deficiency (Alcorn et al., 2008).  These 
actions of JNK to decrease intercellular adhesion may contribute to tumor 
formation.   
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JNK and the tumor micro-environment 
This study has focused on the role of JNK in tumor cells.  However, JNK may 
also play roles within the tumor micro-environment, including expression of 
cytokines / growth factors (Das et al., 2009) and the function of the innate and 
adaptive immune systems (Gao et al., 2005; Tao et al., 2007; Das et al., 
2009).  Thus, the finding that Jnk1-/- mice exhibit decreased (and Jnk2-/- mice 
exhibit increased) carcinogen-induced skin cancer compared with wild-type 
mice (Chen et al., 2001; She et al., 2002) may be explained, in part, by the 
opposite effects of JNK1 and JNK2-deficiency on CD8 T cell-mediated tumor 
immunosurveillance (Gao et al., 2005; Tao et al., 2007).  Moreover, the 
effects of JNK1-deficiency to suppress carcinogen-induced hepatocellular 
carcinoma (Hui et al., 2008) may be accounted for, in part, by decreased 
expression of inflammatory cytokines (e.g. IL6 and TNF) by hepatic innate 
immune cells (Das et al., 2009).  These considerations indicate that a full 
understanding of the role of JNK in cancer should take account of JNK 
functions in both tumor cells and the tumor micro-environment.    
 
JNK and tumor suppression 
The results of this study demonstrate that Ras-induced transformation of 
primary MEF and Ras-induced lung tumor formation requires JNK.  However, 
these data do not exclude the possibility that JNK may also contribute to 
tumor suppression.  Indeed, published studies have implicated JNK in both 
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tumor formation and tumor suppression (Davis, 2000; Whitmarsh and Davis, 
2007).  Precedent for this type of dual activity during tumor development is 
provided by the TGF- pathway (Siegel and Massague, 2003).  Roles of the 
JNK pathway in tumor suppression most often correlate with late-stage tumor 
metastasis (Whitmarsh and Davis, 2007).  Indeed, studies of human cancer 
genetics and biochemical analysis of human tumor-derived cell lines support 
the conclusion that the JNK signal transduction pathway may contribute to 
metastasis suppression (Whitmarsh and Davis, 2007).  Moreover, Ras-
transformation of established cell lines demonstrates that loss of JNK can 
cause increased metastatic potential (Kennedy et al., 2003).  Further studies 
will be required to formally test the hypothesis that JNK may act as a 
suppressor of late-stage tumor development in vivo.  In contrast, this study 
demonstrates that JNK is required for early stage Ras-induced tumor 
formation in vitro and in vivo.   
 
Conclusions 
This study demonstrates that Ras-induced transformation of primary MEF in 
vitro requires JNK.  Similarly, JNK is required for Ras-induced lung tumor 
development in vivo.  These data indicate that JNK plays a critical role in Ras-
induced tumor initiation.  
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Figure II.1  Growth properties of Trp53-/- Jnk1-/- Jnk2-/- embryonic 
fibroblasts.   
A)  Loss of contact growth inhibition in Trp53-/- MEF is prevented by disruption 
of Jnk1 plus Jnk2.  WT, Trp53-/-, and Trp53-/- Jnk-/- MEF were examined using 
phase-contrast microscopy.  Representative images are shown of cells 
growing in sparse (upper panels) or confluent (lower panels) culture 
conditions.   
B)  Growth of Trp53-/- cells in low serum is prevented by disruption of Jnk1 
plus Jnk2.  WT, Trp53-/- and Trp53-/- Jnk-/- MEF were plated on day 0 (D= 0) 
and cultured for seven days (D = 7) in medium supplemented with different 
concentrations of serum.  Relative cell numbers were measured by staining 
with crystal violet.  The data are presented as means ± standard deviation 
(n=5) and are representative of three independent experiments.  Statistically 
significant differences (p < 0.01) between WT MEF and mutant MEF are 
indicated with an asterisk.   
C,D)  Soft agar colony formation by Trp53-/- MEF requires JNK.  Cells were 
grown in soft agar supplemented with 10% serum.  Colony formation was 
assessed after 20 days.  Representative images are shown of colonies 
formed by WT, Trp53-/-  and Trp53-/- Jnk-/- cells (C).  The number of colonies 
(> 10 cells) formed by each cell type was counted and is shown in (D).  
Statistically significant differences (P < 0.01) between WT MEF and mutant 
MEF are indicated with an asterisk. 
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Figure II.2  Effect of JNK-deficiency on cadherin expression.   
A)  MEF prepared from Rosa26-CreERT +/- Trp53LoxP/LoxP  Lox-Stop-Lox-
KRasG12D/+ mice (Trp53-/- KrasG12D mice) and Rosa26-CreERT +/- Trp53LoxP/LoxP  
Lox-Stop-Lox-KRasG12D/+ Jnk1LoxP/LoxP Jnk2-/- mice (Trp53-/- KrasG12D Jnk-/- 
mice) were treated with 1 µM 4-hydroxy-tamoxifen (24 h).  The MEF were 
examined by phase contrast microscopy.   
B)  Expression of E-cadherin, N-cadherin, and OB-cadherin in Trp53-/- and 
Trp53-/- Jnk-/- MEF was examined by immunoblot analysis.  The effect of 
activated Ras was examined.   
C)  E-cadherin and N-cadherin expression was examined by 
immunofluorescence microscopy (green).  DNA was stained with DAPI (blue).  
 
 45
 
 
 
 
 
 46
Figure II.3  JNK suppresses stress-induced apoptosis in p53-deficient 
MEF.   
A)  MEF were exposed to the indicated doses of UV radiation.  Lysates were 
prepared at 4 h. post-irradiation and genomic DNA fragmentation was 
measured by ELISA.  Statistically significant differences (P < 0.01) between 
WT MEF and mutant MEF are indicated with an asterisk.   
B)  MEF were exposed to UV radiation (60 J/m2).  Relative cell numbers were 
measured by staining with crystal violet.  The data are presented as means ± 
standard deviation (n=3) and are representative of three independent 
experiments.  Statistically significant differences (P < 0.01) between WT MEF 
and mutant MEF are indicated with an asterisk.   
C)  MEF growing were exposed to UV (60 J/m2).  At 6 h post-irradiation, the 
cells were replated at the indicated dilutions.  Colony formation was assessed 
after 10 days in culture by staining with crystal violet.  Representative images 
are shown.   
D)  Total cell lysates were prepared from MEF at the indicated times after 
exposure to UV radiation (60 J/m2).  The amount of PARP and caspase 3 was 
assessed by immunoblot analysis using antibodies that detect both the 
cleaved (designated with an asterisk) and full length forms of these proteins.  
The expression of -Tubulin was examined to confirm equal loading of each 
lane.   
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Figure II.4  Effect of activated Ras on Trp53-/- MEF and Trp53-/- Jnk-/- 
MEF.   
A)  MEF were exposed to 0 or 60 J/m2 UV-C, harvested at 60 min post-
irradiation, and examined by immunoblot analysis using antibodies to 
phosphoJNK, JNK, and -Tubulin.   
B)  MEF cultures were examined by phase contrast microscopy.  
C)  The saturation density of MEF cultured in medium (10 days) with different 
concentrations of serum was examined by staining with crystal violet (mean ± 
SD; n = 3).   
D,E)  Cell proliferation in medium supplemented with 1% (D) or 10% (E) fetal 
calf serum.  Relative cell number was measured by staining with crystal violet 
(mean ± SD; n = 3).   
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Figure II.5  Ras-mediated signal transduction in Trp53-/- MEF and Trp53-/- 
Jnk-/- MEF.   
A)  MEF were exposed to 0 or 60 J/m2 UV-C and harvested at 60 min post-
irradiation.  The amount of phospho-p38 MAP kinase, phospho-ERK, 
phospho-JNK, and phosphSer473-AKT was measured by multiplexed ELISA 
(mean ± SD; n = 3).   
B)  ROS accumulation was examined by measurement of fluorescence 
intensity in studies of MEF stained with H2DCFDA.  The relative fluorescence 
intensity is indicated in the lower left corner of each panel.   
C)  The effect of rotenone and diphenyleneiodonium chloride (DPI) on ROS 
production by Trp53-/- Ras* MEF was examined by measurement of mean 
fluorescence intensity (mean ± SD; n = 3).  Statistically significant differences 
(P < 0.05) between are indicated with an asterisk.   
D)  The expression of Nox4 and p22phox mRNA by Trp53-/- Ras* MEF and 
Trp53-/- Jnk-/- Ras* MEF was examined by quantitative RT-PCR assays (mean 
± SD; n = 3). Statistically significant differences (P < 0.01) are indicated with 
an asterisk.    
 
 
 
 
 
 51
 
 
 
 
 
 
 
 
 
 
 
 
 
 52
Figure II.6  JNK is required for colony formation in soft agar and tumor 
formation in vivo. 
A,B)  MEF prepared from Rosa26-CreERT Trp53LoxP/LoxP  Lox-Stop-Lox-
KRasG12D/+ mice (Trp53-/- mice) and Rosa26-CreERT Trp53LoxP/LoxP  Lox-Stop-
Lox-KRasG12D/+ Jnk1LoxP/LoxP Jnk2-/- mice (Trp53-/- Jnk-/- mice) were treated 
with 1 µM 4-hydroxy-tamoxifen (24 h).  The MEF were plated in soft agar and 
incubated for 2 weeks.  Representative images of colonies formed by the 
MEF are illustrated (A).  The number of soft agar colonies per plate was 
counted (mean ± SD; n = 6) (B).  Statistically significant differences (P < 
0.001) are indicated with an asterisk.   
C,D)  MEF were injected sub-cutaneously in the flank of host mice. Palpable 
tumor nodules were measured (C).  The mice were euthanized at day 21 
post-injection and the tumor mass (mean ± SD; n = 10) was measured (D).  
Statistically significant differences (P < 0.001) between are indicated with an 
asterisk.   
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Figure II.7  JNK is required for Ras-induced lung tumorigenesis.   
A)  LoxP-Stop-LoxP-KRasG12D/+ mice (Control KRasG12D mice) and LoxP-
Stop-LoxP-KRasG12D/+ Jnk1LoxP/LoxP Jnk2-/- mice (KRasG12D Jnk-/- mice) were 
exposed to Adenovirus-Cre by nasal instillation.  Lung tumors were detected 
by examination of the lungs at 12 weeks post-infection.   
B)  Lung tissue sections prepared from Control KRasG12D mice and KRasG12D 
Jnk-/- mice at 4 weeks and 8 weeks post-infection were stained with 
hematoxylin & eosin.   
C)  The number of hyperplastic lesions per tissue section was measured at 4, 
8, and 12 weeks post-infection.  Significant differences between control and 
JNK-deficient tumors are indicated with an asterisk (P < 0.05; n = 10).   
D)  The number of adenomas (> 0.5 mm) per tissue section was measured at 
4, 8, and 12 weeks post-infection.  Significant differences between control 
and JNK-deficient tumors are indicated with an asterisk (P < 0.05; n = 10). 
E)  Lung sections were stained with an antibody to the proliferation marker 
PCNA (red).  DNA was stained with DAPI (blue).   
F)  Lung extracts prepared from mice treated without Adenovirus-Cre (Control 
and JnkLoxP/LoxP) and with adenovirus-Cre (Ras* and Ras* Jnk-/-) at 12 weeks 
post-infection were examined by immunoblot analysis using antibodies to 
detected PCNA, cleaved PARP, capase 3 (Casp. 3), cleaved caspase 3 
(Casp 3*), and -Tubulin.   
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CHAPTER III 
 
ROLE OF JNK IN A TRP53-DEPENDENT MOUSE MODEL OF BREAST 
CANCER 
 
 
Summary 
 
The cJun NH2-terminal kinase (JNK) signal transduction pathway has 
been implicated in mammary carcinogenesis.  To test the role of JNK, I 
examined the effect of ablation of the Jnk1 and Jnk2 genes in a Trp53-
dependent model of breast cancer using BALB/c mice.  I detected no defects 
in mammary gland development in virgin mice or during lactation and 
involution in control studies of Jnk1-/- and Jnk2-/- mice.  In a Trp53-/+ genetic 
background, the incidence of mammary carcinomas was similar for control 
mice (43%) and Jnk2-/- mice (53%), but was larger in Jnk1-/- mice (70%).  
These data indicate that JNK1 and JNK2 are not essential for mammary 
carcinoma development in a Trp53-/+-BALB/c model of breast cancer.  In 
contrast, this analysis suggests that JNK may partially contribute to tumor 
suppression.  This conclusion is consistent with the finding that the tumor-free 
survival of JNK-deficient Trp53-/+ mice was significantly reduced compared 
with control Trp53-/+ mice.   
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Introduction 
The cJun NH2-terminal kinase (JNK) group of signaling enzymes are 
activated by cytokines / growth factors and also by exposure to environmental 
stress (Davis, 2000).  Targets of the JNK pathway include members of the 
activator protein 1 (AP1) group of transcription factors (e.g. cJun, JunB, and 
JunD).  JNK is therefore a major regulatory mechanism of AP-1 dependent 
gene expression (Davis, 2000).  In addition, JNK can regulate many 
cytoplasmic and nuclear processes (Weston and Davis, 2007).  These studies 
have implicated the JNK signaling pathway in the regulation of cell growth 
and cell death (Davis, 2000).  Dysregulation of the JNK pathway may 
therefore contribute to the development of cancer (Whitmarsh and Davis, 
2007).   
 The role of JNK in cancer has been studied using mouse models that 
are JNK-deficient.  Two genes (Jnk1 and Jnk2) encode isoforms of JNK that 
are ubiquitously expressed (Davis, 2000).  Jnk1-/- mice and Jnk2-/- mice are 
viable, but compound mutant Jnk1-/- Jnk2-/- mice exhibit an early embryonic 
lethal phenotype (Davis, 2000).  Studies using Jnk1-/- mice and Jnk2-/- mice 
indicate that JNK may have isoform-dependent effects on cancer.  Thus, Bcr-
Abl-induced lymphoma (Hess et al., 2002) and carcinogen-induced 
hepatocellular carcinoma (Hui et al., 2008) are suppressed in Jnk1-/- mice.  
Moreover, carcinogen-induced skin cancer is suppressed in Jnk2-/- mice 
(Chen et al., 2001).  Similarly, important roles for JNK2 have been identified 
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in studies of human glioblastoma, prostate cancer, and lung carcinoma cell 
lines (Bost et al., 1999; Potapova et al., 2000; Yang et al., 2003; Cui et al., 
2006).  Together, these data confirm that both JNK1 and JNK2 can play roles 
in tumor development.   
 The purpose of this study was to test the requirement of JNK1 and 
JNK2 in a mouse model of mammary carcinoma.  Somatic mutation of the 
human p53 gene (TP53) is common in sporadic breast cancer (Wood et al., 
2007).  Furthermore, mammary carcinoma is the most common form of 
cancer in women with heritable mutations in TP53 (Li-Fraumeni syndrome) 
(Birch et al., 2001).  Initial studies using mouse models demonstrated that 
Trp53-/- animals develop lymphoma with high frequency and that Trp53-/+ 
animals display a moderately broader tumor spectrum with slower onset of 
disease (Donehower et al., 1992; Jacks et al., 1994).  Subsequent studies 
using Trp53-/+ mice on a BALB/c strain background demonstrated that, like 
humans with Li-Fraumeni syndrome, mammary carcinoma was frequently 
observed, together with some lymphomas and sarcomas (Kuperwasser et al., 
2000).  The BALB/c mouse model can therefore be used to examine Trp53-
dependent formation of mammary carcinoma.   
 I report that JNK1 and JNK2 are not required for the development of 
mammary carcinoma in the Trp53-/+ BALB/c mouse model.  In contrast, the 
tumor-free survival of JNK-deficient Trp53-/+ mice was reduced compared with 
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control Trp53-/+ mice.  These data suggest that JNK may partially contribute to 
tumor suppression.   
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Materials and Methods 
Mice 
We have described Jnk1-/- mice (Dong et al., 1998) and Jnk2-/- mice (Yang et 
al., 1998) on a C57BL/6J strain background (Das et al., 2009), and mice with 
Trp53 gene ablation (Jacks et al., 1994) on a BALB/cMed strain background 
(Jerry et al., 1998).  The mice used in this study were backcrossed (ten 
generations) to the BALB/cJ strain (Jackson Laboratories) and were housed 
in a facility accredited by the American Association for Laboratory Animal 
Care (AALAC).  The Institutional Animal Care and Use Committee (IACUC) of 
the University of Massachusetts approved all studies using animals.   
 
Genotype analysis 
Genotype analysis was performed by PCR using genomic DNA as the 
template.  The wild-type Jnk1  (460 bp) and knockout Jnk1 (390 bp) alleles 
were identified using the amplimers 5’-CGCCAGTCCAAAATCAAGAATC-3’, 
5’-GCCATTCTGGTAGAGGAAGTTTCTC-3’, and 5’-
CCAGCTCATTCCTCCACTCATG-3’.  The wild-type Jnk2 (400 bp) and 
knockout Jnk2 (270 bp) alleles were identified using the amplimers 5’- 
GGAGCCCGATAGTATCGAGTTACC-3’, 5’-
GTTAGACAATCCCAGAGGTTGTGTG-3’, and 5’-
CCAGCTCATTCCTCCACTCATG-3’.  The wild-type p53  (470 bp) and 
knockout p53 (700 bp) alleles were identified using the amplimers 5’-
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TATACTCAGAGCCGGCCT-3’, 5’-ACAGCGTGGTGGTACCTTAT-3’ and 5’-
CTATCAGGACATAGCGTTGG-3’.   
 
Analysis of tissue morphology 
Mammary gland development was examined in virgin female mice (8 to 10 
weeks of age), lactating mice (1 week post partum), and mice with mammary 
gland involution (pups removed at 1 week post-partum).  The fourth inguinal 
mammary gland pair was dissected from each mouse; one gland was 
analyzed by whole mount and the other was formalin-fixed and paraffin-
embedded.   
Whole mounts were performed by spreading the gland on a glass slide 
and incubation (2 – 4 hrs.) with Carnoy’s fixative (60% ethanol, 30% 
chloroform, 10% glacial acetic acid).  The glands were then incubated with a 
graded series of 70%, 50% and 25% ethanol (15 mins each), followed by 5 
minutes in water and stained with carmine alum overnight.  The glands were 
washed in 70%, 90% and 100% ethanol (15 mins each), two changes of 
xylene (30 mins), and then mounted with Permount (Fisher Scientific).  
 Analysis of tissue sections was performed using tissue fixed in 10% 
formalin for 24h, dehydrated, and embedded in paraffin.  Sections (7µm) were 
cut and stained using hematoxylin and eosin (Biocare Medical).  
Immunofluorescence analysis was performed using de-parafinized sections 
treated with the endogenous Biotin-Blocking kit (Invitrogen), staining (4°C, 
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12h) with biotin-conjugated anti-PCNA, and the incubation (25 °C, 1hr) with 
AlexaFluor633-conjugated Streptavidin.  The sections on coverslips were 
washed and mounted on slides using VectaShield medium containing DAPI 
(Vector Labs.).  Images were examined using a Leica TCS SP2 confocal 
microscope.   
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Results 
Effect of JNK-deficiency on mammary gland development.   
We backcrossed Jnk1-/- mice (Dong et al., 1998) and Jnk2-/- mice (Yang et al., 
1998) to the BALB/cJ strain background.  To test whether JNK-deficiency 
altered mammary gland development, I examined Jnk1-/- and Jnk2-/- BALB/c 
mice.  No defects were detected in whole mount preparations of fourth 
inguinal mammary glands of JNK-deficient virgin female mice compared with 
control mice (Figure III.1A).  Sections prepared from these mammary glands 
confirmed that JNK-deficiency did not cause major defects in virgin mammary 
gland development (Figure III.1B).   
 Pregnancy causes major changes in mammary gland development, 
including the formation of alveoli.  Sections prepared from the fourth inguinal 
mammary glands of JNK-deficient lactating mice and control lactating mice 
were similar (Figure III.2).  Indeed, sections stained for proliferating cell 
nuclear antigen (PCNA) indicated that JNK-deficiency did not alter epithelial 
cell proliferation in the lactating mammary gland (Figure III.2).   
 Involution of the lactating mammary gland occurs after weaning pups.  
I compared sections of the fourth inguinal mammary glands prepared on day 
2 and day 3 following weaning.  No defects in involution were detected in 
JNK-deficient mice compared with control mice (Figure III.3).   
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 Together, these data demonstrate that JNK1-deficiency and JNK2-
deficiency did not cause detected changes in mammary gland development.   
Effect of JNK-deficiency on tumor development in Trp53-/- BALB/c mice.   
I examined the tumor-free survival of Trp53-/- mice, Jnk1-/- Trp53-/- mice, and 
Jnk2-/- Trp53-/- mice on a BALB/c strain background.  The mice rapidly 
developed cancer and died (Figure III.4A).  No significant differences in 
tumor-free survival between control and JNK-deficient mice were detected.  
Pathological examination of the mice demonstrated, as expected, a high 
incidence of lymphoma (Figure III.4B).  The second most frequent type of 
tumor detected in Trp53-/- mice and Trp53-/- Jnk2-/- mice was 
hemangiosarcoma (Figure III.4B).  In contrast, Jnk1-/- Trp53-/- mice displayed 
fewer hemangiosarcomas and a higher incidence of lymphoma compared 
with Trp53-/- mice (Figure III.4B).  These data suggest that JNK1 may 
influence the tumor spectrum of Trp53-/- mice.  Indeed, a low incidence of 
mammary carcinoma was observed in both male and female Jnk1-/- Trp53-/- 
mice, but not in Trp53-/- mice or Trp53-/- Jnk2-/- mice (Figure III.4B).  The 
presence of mammary carcinoma in Jnk1-/- Trp53-/- mice indicates that JNK1 
may be relevant to breast cancer.   
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Effect of JNK-deficiency on tumor development in Trp53-/+ BALB/c mice.   
I performed studies of tumor-free survival of Trp53-/+ mice, Jnk1-/- Trp53-/+ 
mice, and Trp53-/+ Jnk2-/- mice on a BALB/c strain background.  Tumor 
development in the Trp53-/+ mice was significant delayed compared with 
Trp53-/- mice (Figures III.4 and III.5).  Interestingly, JNK1-deficiency (P = 
0.026) and JNK2-deficiency (P = 0.012) caused significantly shortened tumor-
free survival compared with control Trp53-/+ BALB/c mice (Figure III.5A).  
Pathological analysis demonstrated that mammary carcinoma was the most 
common type of tumor detected.  The incidence of mammary carcinoma was 
similar for control mice (43%) and Jnk2-/- mice (53%), but was larger in Jnk1-/- 
mice (70%) (Figure III.5B).  Analysis of mammary carcinoma-free survival of 
Trp53-/+ mice, Jnk1-/- Trp53-/+ mice, and Jnk2-/- Trp53-/+ mice demonstrated 
that JNK1-deficiency (P = 0.018) and JNK2-deficiency (P = 0.039) 
significantly decreased the survival compared with control Trp53-/+ mice 
(Figure III.6A).  No significant difference in mammary carcinoma-free survival 
between JNK1-deficient mice and JNK2-deficient mice was detected (Figure 
III.6A).   
 Together, these data indicate that JNK1 and JNK2 are not required for 
mammary carcinoma development in the Trp53-/+ BALB/c mouse model.  
However, both JNK1 and JNK2 can influence breast cancer development.  It 
appears that JNK can contribute to tumor suppression.   
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Discussion 
JNK1 and JNK2 are not required for the development of mammary 
carcinoma in the Trp53  BALB/c mouse model.   
It is established that JNK plays a critical in the development of some forms of 
cancer (Davis, 2000).  Thus, carcinogen-induced hepatocellular carcinoma 
(Hui et al., 2008) and BcrAbl-induced lymphoma (Hess et al., 2002) are 
strongly suppressed in Jnk1-/- mice and carcinogen-induced skin cancer is 
suppressed in Jnk2-/- mice (Chen et al., 2001).  Moreover, studies of 
glioblastoma, prostate cancer, and lung carcinoma cell lines have identified 
important roles for JNK2 (Bost et al., 1999; Potapova et al., 2000; Yang et al., 
2003; Cui et al., 2006).  Together, these data confirm that JNK plays an 
important role in cancer development.   
 The results of this study suggest that JNK may play a different role in 
mammary carcinogenesis because neither JNK1-deficiency nor JNK2-
deficiency in the Trp53 BALB/c mouse model caused a reduction in the 
incidence of mammary carcinoma.  This observation strongly contrasts with 
the finding that JNK-deficiency can markedly suppress hepatocellular 
carcinoma, lymphoma, and skin cancer (Chen et al., 2001; Hess et al., 2002; 
Hui et al., 2008).   
 Although JNK1-deficiency and JNK2-deficiency did not suppress 
mammary carcinogenesis in the Trp53 BALB/c mouse model, we cannot 
exclude the possibility that defieiency of both JNK1 plus JNK2 might reduce 
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the formation of mammary carcinoma.  Indeed, the Jnk1 and Jnk2 genes may 
have partially redundant functions (Tournier et al., 2000; Jaeschke et al., 
2006; Das et al., 2007; Das et al., 2009).  Studies of compound mutants with 
disruption of Jnk1 plus Jnk2 are required.  The early embryonic lethal 
phenotype of Jnk1-/- Jnk2-/- mice (Kuan et al., 1999) makes such studies 
difficult.  Nevertheless, the effect of compound JNK-deficiency on mammary 
carcinoma development needs to be tested in future studies.   
 
JNK and tumor suppression 
The analysis of JNK1-deficiency and JNK2-deficiency in the Trp53 BALB/c 
mouse model of mammary carcinoma development demonstrates that neither 
JNK1 nor JNK2 is required for breast tumorigenesis (Figures III.5 and III.6).  
In contrast, the mammary carcinoma-free survival of both Jnk1-/- mice and 
Jnk2-/- mice was significantly reduced compared with control mice (Figure 
III.6).  These data suggest that JNK may have a tumor suppressor role in 
breast cancer.  This conclusion is consistent with the observation that JNK2-
deficiency increases breast cancer in a transgenic mouse model with 
expression of polyoma virus T antigen (Chen et al., 2010).  Moreover, human 
genetic analysis has identified mutations in the JNK signaling pathway in 
breast cancer that correlate with tumor suppression and metastasis 
(Whitmarsh and Davis, 2007).  Specifically, loss-of-function mutations in 
MKK4, a human gene that encodes an activator of JNK, is mutated at low 
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frequency in human breast cancer (Teng et al., 1997; Su et al., 1998; Debies 
and Welch, 2001; Su et al., 2002).  It is likely that JNK1-deficiency and JNK2-
deficiency in the mouse may phenocopy the effects of MKK4 gene mutation 
on breast cancer in humans.  The molecular mechanism of tumor 
suppression by the JNK signaling pathway is unclear, but may be related to a 
requirement of JNK for genetic stability (Chen et al., 2010).  Indeed, it has 
been reported that genes that encode DNA repair enzymes are over-
represented as targets of JNK pathway signaling (Hayakawa et al., 2004).   
Conclusions 
I tested the hypothesis that JNK1 or JNK2 plays a critical role during breast 
cancer development.  I found that neither JNK1 nor JNK2 is required for 
mammary carcinoma in the Trp53 BALB/c mouse model.  Breast tumor-free 
survival was significantly reduced by JNK1-deficiency or JNK2-deficiency.  
These data suggest that that JNK1 and JNK2 may play a role in mammary 
carcinoma suppression.   
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Figure III.1  Effect of JNK-deficiency in virgin mice on breast 
development.   
A)  Whole mount preparations of the fourth inguinal mammary gland of 10 
week-old female virgin mice were stained with carmine red.  Representative 
images are presented.  Scale bar: 5 mm (upper panel); 800 µm (lower panel).   
B)  Sections of the breast tissue were stained with hematoxylin and eosin.  
Representative images are presented. Scale bar: 100 µm.   
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Figure III.2  Effect of JNK-deficiency on breast development during 
lactation.   
Sections of the fourth inguinal mammary gland of female mice at day 7 post-
partum were examined by staining with hematoxylin and eosin (upper 
panels).  Sections were also stained with an antibody to the proliferation 
marker PCNA (red) and the DNA stain DAPI (blue) (lower panels).  Scale bar:  
200µm (upper panel); 50 µm (lower panel).   
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Figure III.3  Effect of JNK-deficiency on mammary gland involution.   
The pups were removed from female mice at day 7 post-partum to induce 
mammary gland involution.  Sections of the fourth inguinal mammary gland 
were examined at two days or three days post-weaning by staining with 
hematoxylin and eosin.  Scale bar:  200µm.   
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Figure III.4  Effect of JNK-deficiency on p53-/- mouse survival. 
A)  Kaplan-Meier analysis of the tumor-free survival of wild-type (WT), Jnk1-/-, 
Jnk2-/-, p53-/-, Jnk1-/- p53-/-, and p53-/- Jnk2-/- mice is presented.  No 
statistically significant differences between p53-/-, Jnk1-/- p53-/-, and p53-/- 
Jnk2-/- mice were detected (Log-rank test, P> 0.05).  The data represent 
groups of 44 - 62 mice.  These groups include equal numbers of male and 
female mice.   
B)  The spectrum of tumors detected in p53-/-, Jnk1-/- p53-/-, and p53-/- Jnk2-/- 
mice following euthanasia is presented.   
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Figure III.5  Effect of JNK-deficiency on p53-/+ mouse survival. 
A)  Kaplan-Meier analysis of the tumor-free survival of wild-type (WT), Jnk1-/-, 
Jnk2-/-, p53-/+, Jnk1-/- p53-/+, and p53-/+ Jnk2-/- mice is presented.  The tumor-
free survival of p53-/+ Jnk1-/- mice and p53-/+ Jnk2-/- mice was reduced 
compared with p53-/+ mice (Log-rank test, P = 0.026 and 0.012, respectively).  
The data represent groups of 20 female mice.   
B)  The spectrum of tumors detected in p53-/+, Jnk1-/- p53-/+, and p53-/+ Jnk2-/- 
female mice following euthanasia is presented.   
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Figure III.6  Effect of JNK-deficiency on mammary carcinoma-free 
survival. 
A)  Kaplan-Meier analysis of the mammary carcinoma-free survival of p53-/+, 
Jnk1-/- p53-/+, and p53-/+ Jnk2-/- mice is presented.  JNK1-deficiency and 
JNK2-deficiency caused reduced mammary carcinoma-free survival 
compared with p53-/+ mice (Log-rank test, P = 0.018 and 0.039, respectively).   
B)  Sections of mammary carcinoma detected in p53-/+, Jnk1-/- p53-/+, and 
p53-/+ Jnk2-/- female mice were stained with hematoxylin and eosin.  
Representative sections are presented.   
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CHAPTER IV 
ROLE OF JNK IN MOUSE MAMMARY GLAND DEVELOPMENT 
 
Summary 
The cJun NH2-terminal kinase (JNK) is implicated in the developmental 
morphogenesis of epithelial organs.  To test the role of JNK in the mammary 
gland, I prepared primary mouse mammary epithelial cell and organoid 
cultures.  Compound ablation of the ubiquitously expressed genes Jnk1 plus 
Jnk2 demonstrated that JNK was not required for epithelial cell proliferation or 
motility, but JNK-deficiency did cause increased branching morphogenesis in 
vitro.  Transplantation assays confirmed that JNK suppressed branching 
morphogenesis in vivo.  JNK-deficiency did not prevent mammary gland 
formation, but did cause a partial defect in the lumenal clearance of cells.  
Together, these data demonstrate that JNK contributes to the normal 
development of the mammary gland in virgin mice.   
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Introduction 
The formation of epithelial organs requires the co-ordinated growth and 
movement of epithelial cell sheets.  These developmental processes are 
critically regulated by many mechanisms, including cytokine and endocrine 
signal transduction pathways.  One signaling pathway that has been 
implicated in epithelial organ morphogenesis is the cJun NH2-terminal kinase 
(JNK) signaling pathway (Davis, 2000; Xia and Karin, 2004).  Thus, genetic 
analysis of Drosophila demonstrates that JNK (basket) is essential for the 
morphogenetic epithelial cell movements that occur during dorsal closure (Ip 
and Davis, 1998), thoracic closure (Zeitlinger and Bohmann, 1999), imaginal 
disc development (Agnes et al., 1999), and formation of the egg dorsal 
appendages and micropyle (Suzanne et al., 2001).  Studies of mammalian 
development demonstrate that JNK is required for closure of the optic fissure 
(Weston et al., 2003), eyelid closure (Zhang et al., 2003; Weston et al., 2004), 
and neural tube closure (Kuan et al., 1999).  Key molecular mechanisms that 
may underly these processes include a requirement of JNK for paxillin 
phosphorylation and epithelial cell motility (Huang et al., 2003) and a 
requirement of JNK for actin polymerization-dependent cell protrusions at the 
leading edge of the epithelial cell sheet (Homsy et al., 2006).  An 
understanding of the role of JNK in these developmental processes is 
important because the mechanisms may be relevant to both normal 
physiology and to disease states (Davis, 2000; Xia and Karin, 2004).   
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 The purpose of this study was to test whether JNK was required for 
mammary gland development (Whyte et al., 2009).  Indeed, JNK may play a 
critical role in morphogenesis of the breast epithelium (Murtagh et al., 2004; 
Zhan et al., 2008).  These authors report that the drug SP600125 inhibits both 
JNK activity and lumenal clearance of mammary epithelial cells (Murtagh et 
al., 2004; Zhan et al., 2008).  However, SP600125 exhibits poor selectivity for 
JNK (Bain et al., 2003).  It is therefore unclear whether JNK inhibition 
mediates the effects of SP600125 on morphogenesis of the breast epithelium.  
Moreover, detailed studies of breast epithelium development (Ewald et al., 
2008) indicate that this morphogenetic process differs substantially from other 
epithelial morphogenetic movements that are known to be JNK-dependent 
(Davis, 2000; Xia and Karin, 2004).  Thus, JNK is required for shape changes 
in the cells that form the leading edge of the epithelial cell sheet prior to co-
ordinated cell movements (Homsy et al., 2006).  In contrast, elongating 
mammary epithelial cell ducts form a multi-layer epithelium that moves co-
ordinately without extension of leading edge cells (Ewald et al., 2008).  
Whether JNK contributes to this process during mammary gland development 
is unclear.   
 The JNK protein kinase in mammals is encoded by two ubiquitously 
expressed genes (Jnk1 and Jnk2) and by a third gene (Jnk3) that is 
selectively expressed in the brain (Davis, 2000).  I have not detected 
developmental defects in mammary gland development in Jnk1-/- mice or 
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Jnk2-/- mice (unpublished observation).  Since JNK1 and JNK2 display 
partially redundant functions (Tournier et al., 2000; Jaeschke et al., 2006), I 
examined the effect of compound deficiency of JNK1 plus JNK2.  Compound 
Jnk1-/- Jnk2-/- mice die during embryonic development (Kuan et al., 1999).  
We therefore employed a conditional gene ablation strategy.  This 
experimental approach enabled the examination of the role of JNK in primary 
cultures of mammary epithelial cells and mammary gland organoids in vitro.  
Furthermore, transplantation assays enabled the analysis of the role of JNK in 
mammary gland development in vivo.  I report that JNK is not required for 
mammary epithelial cell motility in vitro or for the formation of mammary 
epithelial cell ducts.  However, JNK contributes to branching morphogenesis 
of mammary epithelium in vivo and in vitro.  Together, these observations 
indicate that JNK plays an important role in mammary gland development.   
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Materials and Methods 
Mice 
We have described Jnk2-/- mice (Yang et al., 1998) and mice with conditional 
expression of Jnk1 (Das et al., 2007).  Nude mice (strain NU/J (Stock # 
002019)), mice with conditional expression of KRasG12D (Jackson et al., 2001) 
(strain B6.129S4-Krastm4Tyj/J (Stock # 008179)), mice with conditional 
expression of Trp53 (Marino et al., 2000) (strain B6.129P2-Trp53tm1Brn/J 
(Stock # 008462)), mice expressing 4-hydroxy-tamoxifen-stimulated Cre 
(Badea et al., 2003) (strain B6;129-Gt(ROSA)26Sortm1(cre/ERT)Nat/J (Stock # 
004847)), and Villin-Cre mice (Madison et al., 2002) (strain B6.SJL-Tg(Vil-
cre)997Gum/J (Stock # 004586)) were obtained from the Jackson Laboratory.  
The mice used in this study were backcrossed to the C57BL/6J strain 
(Jackson Laboratories) and were housed in a facility accredited by the 
American Association for Laboratory Animal Care (AALAC).  The Institutional 
Animal Care and Use Committee (IACUC) of the University of Massachusetts 
approved all studies using animals.   
 
Genotype analysis 
Genotype analysis was performed by PCR using genomic DNA as the 
template.  The Jnk1LoxP (1.1kb) and Jnk1 (0.4kb) alleles were identified using 
the amplimers 5’-CCTCAGGAAGAAAGGGCTTATTTC-3’ and 5’-
GAACCACTGTTCCAATTTCCATCC-3’. The wild-type Jnk2 (400 bp) and 
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knockout Jnk2 (270 bp) alleles were identified using the amplimers 5’- 
GGAGCCCGATAGTATCGAGTTACC-3’, 5’-
GTTAGACAATCCCAGAGGTTGTGTG-3’, and 5’-
CCAGCTCATTCCTCCACTCATG-3’.  The wild-type Trp53 (288 bp) and 
Trp53LoxP (370 bp) alleles were identified using the amplimers 5’-
AGCACATAGGAGGCAGAGAC-3’ and 5’-CACAAAAACAGGTTAAACCCAG-
3’.  The Trp53 (612 bp) allele was identified using the amplimers 5’-
CACAAAAACAGGTTAAACCCAG-3’ and 5’-
GAAGACAGAAAAGGGGAGGG-3’.  The wild-type KRas  (285 bp), KRasG12D 
(315 bp), and Lox-Stop-LoxP-KRasG12D (600 bp) alleles were identified using 
the amplimers 5’-GGGTAGGTGTTGGGATAGCTG-3’ and 5’-
TCCGAATTCAGTGACTACAGATGTACAGAG-3’.  The Rosa26  (600 bp) and 
Rosa26-CreERT (300 bp) alleles were identified using the amplimers 5’-
GCGAAGAGTTTGTCCTCAACC-3’, 5’-GGAGCGGGAGAAATGGATATG-3’, 
and 5’-AAAGTCGCTCTGAGTTGTTAT-3’.  The Villin-Cre allele (450 bp) was 
detected using the amplimers 5’-TTACTGACCGTACACCAAATTTGCCTGC-
3’ and 5’- CCTGGCAGCGATCGCTATTTTCCATGAGTG-3’.   
 
Cre-mediated recombination 
Mice were treated with tamoxifen (Sigma, T5648) to activate Cre-mediated 
recombination in animals with an inducible Cre recombinase (strain B6;129-
Gt(ROSA)26Sortm1(cre/ERT)Nat/J).  The tamoxifen was dissolved in sunflower 
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seed oil (10 mg/mL).  Mice were treated by intraperitoneal injection with 1 mg 
tamoxifen each day for three consecutive days.  Mammary glands were 
harvested three days after the last injection.   
 
Mammary gland transplantation assays 
Transplantation assays were performed using procedures described 
previously (Young, 2000).  Donor mice were euthanized and 1mm3 fragments 
of the fourth inguinal mammary glands were removed aseptically and stored 
in DMEM on ice.  Host mice (3 - 4 week old female nude mice) were 
anesthetized.  The fourth inguinal mammary gland on one side was excised, 
a small pocket was formed in the cleared fat pad proximal to the inguinal 
lymph node, and a fragment of donor mammary tissue was placed in the 
pocket.  The same procedure was performed on the contralateral side.  Each 
host mouse was transplanted with both control and JNK-deficient mammary 
tissue.   
 
Mammary gland analysis 
The fourth inguinal mammary gland was excised, spread on a glass slide and 
fixed (2 – 4 hrs.) in Carnoy’s fixative (60% ethanol, 30% chloroform, 10% 
glacial acetic acid). The glands were rinsed with a series of 70%, 50% and 
25% ethanol (15 mins each) and then water (5 mins), stained with carmine 
alum overnight, rinsed with 70%, 90% and 100% ethanol (15 mins each), and 
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then twice with xylene (30 mins).  The glands were mounted using Permount 
(Fisher Scientific) prior to examination.  Sections (5 µm) prepared from the 
whole mounts following embedding in paraffin were counter-stained with light 
green (American MasterTech).   
 
Primary mammary epithelial culture 
Primary mouse mammary epithelial cells were prepared (Kittrell et al., 1992; 
Novaro et al., 2003).  The inguinal and thoracic mammary glands of five 8 - 
10 week old female virgin mice were removed, minced with two razor blades, 
and digested in DMEM/F12 supplemented with 2 mg/ml collagenase A 
(Roche), 100 units/ml hyaluronidase (Sigma, H3506), 100 units/ml 
penicillin/streptomycin (Invitrogen), and 60 units/ml nystatin (Sigma, N1638) 
for two hours at 37°C with gentle rotation in a final volume of 40 mL. The 
digested tissue was then centrifuged for 10 mins at 1,500 rpm and 10ml of the 
overlying layer of fat and organoids was taken and the remaining supernatant 
was discarded.  The pellet was resuspended in 10 mL of DMEM/F12.  The 
combined suspensions (20 mL) were centrifiged for 10 mins at 1,500 rpm and 
the pellet was resuspended in 4 mL DMEM/F12 plus 40 µl of DNase (2 
units/mL) and shaken gently by hand (2-5 mins) at room temperature prior to 
the addition of 6 mL of DMEM/F12 and centrifugation for 10 mins at 1,500 
rpm to collect mammary epithelial cells.  Fibroblasts and other contaminating 
cells were separated from the mammary gland epithelial cells by differential 
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centrifugation.  The cell pellet was resuspended in 10 mL of DMEM/F12, 
placed in a centrifuge until 1,500 rpm and then immediately stopped.  This 
procedure was repeated 6 times. The final cell pellet containing mammary 
epithelial cells was resuspended in complete medium [DMEM/F12 plus 1X 
insulin/transferrin/selenium (Sigma, I3146), 5 ng/ml EGF (Sigma, E4127), 50 
µg/ml gentamycin (Sigma G1272), 1X Pen-Strep (Invitrogen), and 5% fetal 
bovine serum], filtered through 70 µm cell strainer (BD Falcon), and plated 
onto collagen-I coated T25 flasks (BD Biosciences). 
 
Immunofluorescence analysis of primary mammary epithelial cell 
cultures 
Cells grown on coverslips were washed with phosphate-buffered saline 
(PBS), fixed in 4% paraformaldehyde (15 min), washed with PBS, and then 
incubated in blocking buffer (0.3% Triton / PBS / 5% normal goat serum) for 1 
hr. at 25 °C.  Incubation with primary antibodies (mouse anti-E-cadherin (Cell 
Signaling Technology) and rabbit anti-pan-cytokeratin (Sigma)) was 
performed in blocking buffer for 14 hr. at 4°C.  The cells were washed and 
incubated with secondary antibody (AlexFluor-633 conjugated goat anti-
mouse Ig or AlexaFluor-488-conjugated goat anti-rabbit (Invitrogen)) in 
blocking buffer (1 hr. at 25 °C).  The coverslips were washed in PBS and 
mounted using VectaShield medium containing DAPI (Vector Labs.).  Images 
were examined using a Leica TCS SP2 confocal microscope.   
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Cell proliferation 
The incorporation of BrdU was examined by plating 500,000 cells in 60 mm 
dishes, incubation for 2 days, and treatment with 10 µM BrdU (16 h).  The 
cells were harvested and processed for examination of BrdU incorporation by 
flow cytomtery (BrdU Flow Kit, BD Pharmingen). Briefly, the cells were fixed, 
permeabilized, incubated with DNase, and then incubated with an FITC-
conjugated anti-BrdU antibody.  The cells were stained with 7-
Aminoactinomycin D prior to analysis by flow cytometry.   
 Cell proliferation was also examined using the WST-1 reagent 
(Roche).  We plated 100,000 cells in 24-well dishes in triplicate.  Absorbance 
at 450 nm was measured using a spectrophotometer after incubation for 1 h.  
The background in this assay was assessed by adding the WST-1 reagent to 
wells containing medium only.  Wst-1 measurements were made using cells 
plated for 4 h and 48 h.   
 
Boyden chamber assays 
Mammary epithelial cells were trypsinized, washed in DMEM/F12, counted 
using a hemocytometer, and 150,000 cells in 0.5 mL DMEM/F12 (containing 
all supplements except serum) were plated in each Boyden chamber (24-well 
format) in triplicate.  Invasion assays were performed using Matrigel-coated 
chambers (BD Matrigel Invasion Inserts, BD Biosciences).  Cell migration 
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assays were performed using chambers (BD Biocoat Control Inserts ) that 
were coated with 15 µg/ml collagen I (BD Biosciences) in PBS overnight at 
4°C and then blocked with 0.25% bovine serum albumin in DMEM/F12 
(Merdek et al., 2007).  Complete medium (supplemented with 5% fetal bovine 
serum) was used as the chemoattractant in the lower chamber.  The cells 
were incubated for 24 h. The cells that did not migrate (and therefore 
remained inside the upper chamber) were removed with a cotton swab.  To 
determine the number of cells that migrated (attached to the underside of the 
membrane), the chambers were rinsed in PBS, fixed in ice-cold methanol (10 
mins), and rinsed in two changes of PBS.  The membranes were removed 
and mounted on a glass slide using VectaShield plus DAPI (Vector Labs).  
Cell nuclei were visualized using a Zeiss Axiovert fluorescence microscope.  
Images were acquired from four different fields on each membrane and nuclei 
were counted using ImageJ software (http://rsb.info.nih.gov/ij).   
 
Mammary organoid culture 
Mammary organoid cultures were prepared (Fata et al., 2007; Ewald et al., 
2008) from the inguinal and thoracic mammary glands of five 8 – 12 week old 
female virgin mice.  The glands were removed, minced with two razor blades 
in parallel, and incubated with 50 mL of digestion medium (2 mg/mL 
collagenase (Sigma), 0.15% trypsin, 10% fetal calf serum, 1 µg/mL insulin, 
0.5 µg/mL gentamycin (Invitrogen)) for 2 hours at 37°C with gentle rotation. 
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The mixture was centrifuged (10 mins at 1,500 rpm), the supernatant 
removed, and the pellet was resuspended in 10 mL of DMEM/F12.  This cell 
suspension was centrifuged (10 mins at 1,500 rpm), the supernatant 
removed, and the pellet resuspended in 4 mL of DMEM/F12 with 40U of 
DNAse.  The suspension was gently shaken by hand (5 mins), and 
centrifuged (10 min at 1,500 rpm). The pellet was then resuspended in 10 mL 
of DMEM/F12 and centrifuged to 1,500 rpm and immediately stopped; this 
procedure was repeated four times to remove single cells.  The resultant 
mammary organoids were resuspended in Matrigel (BD Biosciences) and 
plated in 8 chamber (50 µL per well) chamber slides (BD Biosciences).  The 
Matrigel was allowed to set in a 37°C incubator (30mins) before addition of 
minimal medium (MM: DMEM/F12 plus 1X insulin/transferrin/selenium 
solution and 1X penicillin/streptomycin).  Some wells were treated with 2.5 nM 
FGF2 (Sigma) one day after plating.  The organoids were cultured for 7 days.   
 
Immunofluorescence analysis of mammary organoids 
Staining of mammary organoids was performed (Ewald et al., 2008) using 
chamber slides (BD Biosciences) equilibrated with 25% (w/v) sucrose in PBS 
(1 h), fixed in cold 1:1 methanol:acetone overnight at -20oC, and re-
equilibrated in 25% (w/v) sucrose in PBS (1 h).  The organoids were 
subsequently incubated (1 h) in blocking buffer (5% serum in PBS), a FITC-
conjugated antibody to smooth muscle actin (SMA; Sigma) for 2 h at room 
 93
temperature, rinsed three times with blocking buffer.  AlexaFluor-546-
conjugated-Phalloidin (Invitrogen) was used to stain F-actin.  The coverslips 
were rinsed three times with blocking buffer (one wash with 300 nM DAPI), 
and then mounted with Prolong Gold (Invitrogen).  The coverslips were 
examined using a Leica TCS SP2 confocal microscope.   
 
Immunoblot analysis 
Cell lysates were examined by probing with antibodies to ERK1/2 (Cell 
Signaling), JNK1/2 (BD Biosciences), p53 (Cell Signaling), and -Tubulin 
(Sigma).  Immune complexes were detected using enhanced 
chemiluminescence (NEN). 
 
Analysis of mRNA 
Total RNA was isolated from cell lines and real-time reverse transcription 
PCR was performed using TaqMan probes for Ddr1 (Mm00432251_m1), 
Ddr2 (Mm00445615_m1), Gapdh (#4352339E), Integrin alpha 1 
(Mm01306371_m1), Integrin alpha 2 (Mm00434371_m1), Integrin alpha 5 
(Mm00439797_m1), Integrin alpha 6 (Mm00434375_m1), Integrin beta 1 
(Mm01253230_m1), Mmp2 (Mm01253621_m1), Mmp3 (Mm01168401_m1), 
Mmp9 (Mm00442991_m1), Mmp14 (Mm01318966_m1), Adam17 
(Mm01231071_m1), Sprouty2 (Mm00442344_m1), Timp1 
(Mm00441818_m1), Timp2 (Mm00441825_m1), Timp3 (Mm00441827_m1), 
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and Tgf1 (Mm03024053_m1) (Applied Biosystems).  The relative mRNA 
expression was calculated by normalizing to the amount of Gapdh mRNA in 
each sample.   
 
Analysis of the intestinal epithelium 
Mice were injected intraperitoneally with 100 mg/kg BrdU (Sigma) at 2.5 h 
prior to euthanasia.  Immunohistochemistry on the small intestine and colon 
was performed using 5 µm paraffin sections treated with with Target Retrieval 
Solution (DAKO) and the Vectastain ABC kit (Vector Laboratories).  Sections 
were stained with antibodies to JNK1/2 (Pharmingen), p53 (Cell Signaling), 
BrdU (BD Pharmingen), and phosphoSer63-cJun (Cell Signaling).   
 Intestinal epithelial cells were isolated from the small intestine and 
colon.  A longitudinal incision was made and feces were removed by repeated 
washing with PBS.  The intestines (2–3 mm pieces) were incubated with 
Hanks' balanced salt solution (HBSS) supplemented with 30 mM EDTA (15 
min at 37°C).  The supernatant was aspirated, the epithelial cells were 
recovered by centrifugation, washed with ice-cold PBS, and flash frozen prior 
to biochemical analysis.   
 Colitis-associated colon cancer was examined using the 
azoxymethane/DSS model (Greten et al., 2004).  Briefly, mice (6–8-week-old) 
were injected intraperitoneally with 12.5 mg/kg azoxymethane AOM (Sigma).  
After five days, 2.5% DSS (MW, 36-50 kDa; MP Biomedicals) was given in 
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the drinking water for five days, followed by 16 days of regular water.  This 
cycle was repeated twice (five days of 2.5% DSS and four days of 2% DSS) 
and mice were sacrificed ten days after the last cycle.  Colons were removed, 
flushed with 1xPBS, fixed as “Swiss-rolls” in 10% formalin overnight and 
paraffin-embedded.  Sections (5 μm) were cut stepwise (200 μm) through the 
entire block and stained with H&E.   
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Results 
Isolation of JNK-deficient mammary epithelial cells.   
The Jnk1 and Jnk2 genes are expressed in mammary epithelial cells.  I 
employed a conditional gene ablation strategy to create mice with deficiency 
of JNK1 plus JNK2.  I found that Jnk1LoxP/LoxP Jnk2-/- CreERT mice were viable.  
These mice express a 4-hydroxy-tamoxifen-stimulated Cre recombinase.  I 
treated the Jnk1LoxP/LoxP Jnk2-/- CreERT mice with tamoxifen, isolated mammary 
tissue, and prepared primary mammary epithelial cell cultures.  PCR analysis 
of genomic DNA prepared from mammary tissue and cultured epithelial cells 
demonstrated that tamoxifen caused ablation of the conditional Jnk1 gene 
(Figure IV.1A).  Immunoblot analysis confirmed that JNK protein was not 
detected in mammary tissues or epithelial cells of tamoxifen-treated 
Jnk1LoxP/LoxP Jnk2-/- CreERT mice (Figure IV.1B).   
 To examine the effect of JNK-deficiency on primary mammary 
epithelial cells, I compared cultures of cells prepared from control mice 
(CreERT) and Jnk1LoxP/LoxP Jnk2-/- CreERT mice following treatment with 
tamoxifen.  The epithelial cells were identified by immunofluorescence 
analysis by staining with antibodies to pan-cytokeratin and E-cadherin.  I did 
not detect an effect of JNK-deficiency on the morphology of primary 
mammary epithelial cells (Figure IV.1C).   
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Role of JNK in mammary epithelial cell proliferation.   
It is established that compound JNK-deficiency in primary mouse embryonic 
fibroblasts (MEF) causes p53-dependent senescence (Tournier et al., 2000; 
Das et al., 2007).  Growth of Jnk1-/- Jnk2-/- MEF requires loss-of-function of 
the p53 pathway (Das et al., 2007).  I therefore anticipated that Jnk1/ Jnk2-/- 
primary mammary epithelial cells would also exhibit reduced growth and 
senescence.  However, the morphology of JNK-deficient epithelial cells was 
not typical of senescent cells (Figure IV.2A).  Moreover, cell cycle analysis by 
flow cytometry did not demonstrate a requirement of JNK for proliferation 
(Figure IV.2B).  Indeed, Jnk1/ Jnk2-/- primary mammary epithelial cells 
incorporated significantly more BrdU that control cells, indicating that JNK-
deficiency may increase epithelial cell proliferation (Figure IV.2B).  This 
conclusion was confirmed using the Wst-1 assay to monitor cell proliferation 
(data not shown).  Together, these data demonstrate that the effect of JNK-
deficiency on the proliferation of MEF markedly differs from mammary 
epithelial cells.  Thus, JNK is required for MEF proliferation, but is not 
required for proliferation of mammary epithelial cells.   
 It is unclear whether the failure of JNK-deficient mammary epithelial 
cells to senesce reflects a role of JNK in epithelial cells or whether this role of 
JNK is specific to mammary epithelial cells.  To address this question, I 
examined the effect of JNK-deficiency in intestinal epithelial cells using 
conditional gene ablation in vivo with Villin-Cre (Figure IV.S1).  Compound 
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JNK-deficiency caused no detected defects in the proliferation of intestinal 
epithelial cells (Figure IV.S1A) or colon tumor cells (Figure IV.S1C and D).  
JNK-deficiency causes increased expression of p53 by MEF (Tournier et al., 
2000), but no increase in p53 expression was detected in JNK-deficient 
intestinal epithelial cells (Figure S1B).  Moreover, ionizing radiation caused a 
similar increase in p53 expression by control and JNK-deficient intestinal 
epithelial cells.  Together, these data indicate that the p53-dependent 
senescence of JNK-deficient MEF (Tournier et al., 2000; Das et al., 2007) 
reflects a specific role of JNK in MEF, but not other cell types (e.g. mammary 
and intestinal epithelial cells).   
Role of JNK in mammary epithelial cell migration.   
It is has been reported that JNK is required for actin polymerization-
dependent cell protrusions at the leading edge of epithelial cell sheets during 
morphogenetic movements (Homsy et al., 2006).  It has also been reported 
that paxillin phosphorylation by JNK is essential for epithelial cell movement 
(Huang et al., 2003).  Together, these data indicate that JNK is a critical 
cellular component that is required for cell motility.  To test this hypothesis, I 
prepared cultures of mammary epithelial cells from control mice (CreERT) and 
Jnk1LoxP/LoxP Jnk2-/- CreERT mice following treatment with tamoxifen.  
Comparison of control and Jnk1/ Jnk2-/- primary mammary epithelial cells in 
Boyden chamber assays demonstrated that JNK is not required for cell 
motility.  Indeed, studies using Boyden chambers coated with collagen 
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showed that JNK-deficiency increased mammary epithelial cell motility 
(Figure IV.3A).  Moreover, assays using Boyden chambers with a Matrigel 
layer demonstrated that JNK-deficiency increased mammary epithelial cell 
invasion (Figure IV.3B).  Together, these data do not support a critical role for 
JNK as a positive regulator of primary mammary epithelial cell motility.  This 
finding contrasts with previous reports that JNK plays a key role in epithelial 
cell motility (Huang et al., 2003; Xia and Karin, 2004).  I therefore examined 
mice with JNK-deficiency in the intestinal epithelium (Figure S1).  Epithelial 
cells formed in intestinal crypts migrate on the surface of the villus to create 
the intestinal epithelium.  Intestinal epithelium morphology was not disrupted 
by JNK-deficiency (Figure IV.S1), consistent with a non-essential function of 
JNK in intestinal epithelial cell motility.  Together, these data indicate that JNK 
is not required for epithelial cell motility.   
Role of JNK in mammary branching morphogenesis.   
Branching morphogenesis is an important aspect of the development of the 
mammary gland (Fata et al., 2004; Sternlicht, 2006).  This process can be 
studied in vitro using mammary organoid cultures in the presence of FGF2 
(Ewald et al., 2008).  I prepared cultures of mammary organoids from control 
mice (CreERT) and Jnk1LoxP/LoxP Jnk2-/- CreERT mice following treatment with 
tamoxifen.  The organoids are formed by bilayer structures with luminal 
mammary epithelial cells and basal myoepithelial cells that express smooth 
muscle actin (Deugnier et al., 2002; Bissell et al., 2003).  Branching 
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morphogenesis is regulated by hormones/growth factors and by the 
interaction of the lumenal epithelial cells with basal myoepithelial cells and the 
extracellular matrix (Fata et al., 2004).  Branching morphogenesis was 
detected in cultures of control and Jnk1/ Jnk2-/- mammary organoids (Figure 
IV.4A).  This observation demonstrated that JNK was not required for 
branching morphogenesis.  However, quantitation of the branching indicated 
that JNK-deficient organoids exhibited significantly greater branching 
morphogenesis than control organoids (Figure IV.4B).  Together, these data 
demonstrate that JNK can influence mammary branching morphogenesis.   
Effect of JNK-deficiency on mammary epithelial cell gene expression.   
It is established that the JNK signal transduction pathway can regulate gene 
expression (Davis, 2000).  JNK-regulated gene expression may therefore 
account for the effect of JNK-deficiency on epithelial cell motility and invasion 
(Figure IV.3) and branching morphogenesis (Figure IV.4).  I therefore 
examined the effect of JNK-deficiency on the expression of candidate genes 
that may influence these processes (Figure IV.5).   
 Matrix metalloproteases (MMPs) play key roles in mammary gland 
development (Sternlicht, 2006).  Thus, ADAM17 induces shedding of the EGF 
receptor ligand amphiregulin that can induce expression of MMP2 (Sternlicht 
et al., 2005).  MMP2 (and its activator MMP14) can promote ductal elongation 
(Wiseman et al., 2003), and both MMP3 and MMP9 promote branching 
morphogenesis (Lee et al., 2000; Wiseman et al., 2003).  I found that JNK-
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deficiency caused significantly decreased expression of Mmp2, Mmp9, and 
Mmp14 mRNA (Figure IV.5A).  These changes do not account for the 
increased branching morphogenesis caused by JNK-deficiency.  MMPs and 
ADAM17 are negatively regulated by Tissue Inhibitors of Metalloproteases 
(TIMPs).  Down-regulated expression of TIMP1/2/3 could therefore increase 
MMP and/or ADAM17 activity and therefore influence branching 
morphogenesis (Fata et al., 2004).  Indeed, a significant reduction in Timp1, 
Timp2, and Timp3 mRNA expression was caused by JNK-deficiency (Figure 
5B).  In contrast, the expression of two other genes that are implicated in 
branching morphogenesis (Tgf1 and Sprouty2) was unaffected by JNK-
deficiency (Figure IV.5B).  Together, these data suggest that decreased TIMP 
expression may contribute to increased branching morphogenesis caused by 
JNK-deficeincy.   
 The increased motility and invasion activity of JNK-deficient mammary 
epithelial cells detected in Boyden chamber assays may reflect altered 
integrin expression.  I found decreased expression of 1, 5, 6, and 1 
integrins and also decreased expression of the collagen receptor DDR1 in 
JNK-deficient mammary epithelial cells (Figure IV.5C).  Previous studies have 
implicated integrin 2, integrin 1, and DDR1 in mammary gland development 
(Fata et al., 2004), but decreased expression of these proteins is not 
predicted to cause the increased motility, invasion, and branching 
morphogenesis caused by JNK-deficiency (Figures IV.2 - 4).  The mechanism 
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that accounts for increased motility and invasion by JNK-deficient mammary 
epithelial cells is therefore unclear.   
Effect of JNK-deficiency on mammary gland development.   
I employed transplantation assays to test the role of JNK in mammary gland 
development.  Control (CreERT) tissue was transplanted in one cleared 
mammary gland of a female nude mouse and Jnk1/ Jnk2-/- CreERT tissue 
was transplanted in the contralateral gland of the same recipient mouse.  
Analysis of mammary gland development at 8 weeks following transplantation 
demonstrated that JNK-deficiency did not prevent the elaboration of 
mammary epithelial ducts (Figure IV.6A).  However, JNK-deficiency caused 
an increase in the number of branches (Figure IV.6B and C).  These data 
indicate that JNK can influence mammary branching morphogenesis in vivo.   
 To test whether JNK may alter the early time course of mammary 
gland development, I examined mice at 2 weeks following transplantation.  
This analysis demonstrated the presence of terminal end buds (TEBs) in 
glands formed by control and JNK-deficient tissue (Figure IV.6D).  Sections of 
TEBs formed by transplantation of control tissue demonstrated the presence 
of a lumenal space (Figure IV.6E).  In contrast, this terminal end bud lumenal 
space was partially filled with cells in glands formed by transplantation of 
JNK-deficient tissue.  These data indicate that JNK-deficiency disrupts TEB 
morphology during mammary gland development.  Moreover, JNK-deficiency 
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increased the number of branches detected at 2 weeks following 
transplantation (Figure IV.6F).   
Effect of JNK-deficiency on mammary tumorigenesis.   
JNK-deficiency influences the proliferation, motility, invasion activity, and 
branching morphogenesis in vitro (Figures IV.2 - 4) and mammary gland 
development in vivo (Figure IV.6).  These data indicate that JNK may regulate 
mammary tumor development.  To test this hypothesis, I examined the effect 
of mutational activation of the endogenous KRas gene in vivo.  
Transplantation assays were performed using donor tissue from control mice 
(LoxP-Stop-LoxP-KRasG12D/+ CreERT) and mice with conditional expression of 
JNK (LoxP-Stop-LoxP-KRasG12D/+ Jnk1LoxP/LoxP Jnk2-/-  CreERT).  The recipient 
nude mice were transplanted with both control tissue and JNK-deficient tissue 
in the fourth inguinal gland pair.  The transplanted mice were treated with 
tamoxifen to induce expression of activated Ras (KRasG12D) and to ablate the 
conditional Jnk1 gene.  No tumors were detected in these mice within 6 
months of transplantation.   
 The failure of activated Ras to cause mammary carcinoma in this 
model may reflect the tumor suppressive anti-estrogen actions of tamoxifen.  
Alternatively, the KRasG12D oncogene may require a co-operating mutation to 
efficiently induce breast cancer (Podsypanina et al., 2008).  I therefore 
examined the effect of p53 loss-of-function on KRasG12D -induced breast 
cancer.  Transplantation assays were performed using donor tissue from 
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control mice (LoxP-Stop-LoxP-KRasG12D/+ Trp53LoxP/LoxP CreERT) and mice with 
conditional expression of JNK (LoxP-Stop-LoxP-KRasG12D/+ Jnk1LoxP/LoxP Jnk2-
/- Trp53LoxP/LoxP CreERT).  Tumors were recipient in mice at 15 weeks post-
transplantation.  Cohorts of mice transplanted with control and JNK-deficient 
tissue have been generated, but data from these studies is not yet available.   
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Discussion 
Mice with defects in JNK expression have provided insight into biological 
function of the JNK signaling pathway (Davis, 2000; Weston and Davis, 
2007).  However, the ubiquitously expressed Jnk1 and Jnk2 genes have 
partially redundant functions (Tournier et al., 2000; Jaeschke et al., 2006) and 
compound mutant Jnk1-/- Jnk2-/- mice die during mid-embryogenesis (Kuan et 
al., 1999).  Studies of the effect of compound JNK-deficiency have therefore 
largely focused on an analysis of MEF (Tournier et al., 2000).  This is a 
problem because MEF are not representative of many differentiated cell 
types.  Recently, progress has been made towards the creation of mice with 
conditional and chemical genetic Jnk alleles (Jaeschke et al., 2006; Das et 
al., 2007) that enable the analysis of cell types that are relevant to specific 
physiological processes (Das et al., 2009).   
The focus of this study was to examine the role of JNK in mammary 
epithelial cells.  We report that JNK contributes to mammary gland 
development.  However, some of the specific functions of JNK in mammary 
epithelial cells differ from those previously identified in MEF.   
 
JNK is not essential for mammary epithelial cell proliferation or motility 
Compound JNK-deficiency in MEF causes increased p53 expression and 
senescence (Tournier et al., 2000; Das et al., 2007).  In contrast, no 
differences in proliferation between control and JNK-deficient mammary 
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epithelial cells were detected in vitro (Figure IV.2).  Moreover, transplantation 
assays demonstrated that JNK-deficient cells retained sufficient proliferative 
capacity to form a mammary gland in vivo (Figure IV.6).  These data 
demonstrate that, in contrast to MEF, JNK is not essential for proliferation of 
mammary epithelial cells.  This conclusion may apply to other epithelial cells 
because studies of intestinal epithelial cells also demonstrated that JNK is not 
required for proliferation (Figure IV.S1).  Thus, the effect of JNK-deficiency to 
engage the p53 pathway may represent a specialized response of MEF to 
loss of JNK signaling.   
 JNK signaling has been implicated in the regulation of cell motility (Xia 
and Karin, 2004).  The role of JNK may be mediated by a requirement of JNK 
for paxillin phosphorylation (Huang et al., 2003) and by a requirement of JNK 
for actin polymerization-dependent cell protrusions (Homsy et al., 2006).  
Nevertheless, we did not detect defects in mammary epithelial cell motility 
caused by JNK-deficiency.  In contrast, JNK-deficiency caused an increase in 
motility in Boyden chamber assays (Figure IV.3A).  Similarly, JNK-deficiency 
caused increased invasion of mammary epithelial cells through a Matrigel 
layer (Figure IV.3A).  Furthermore, transplantation assays demonstrated that 
JNK-deficiency did not prevent the formation of mammary epithelial cell ducts 
in the developing mammary gland in vivo (Figure IV.6).  Studies of intestinal 
epithelial cells confirmed that JNK was not essential for epithelial cell motility 
in vivo (Figure IV.S1).  Together, these data demonstrate that JNK is not 
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essential for epithelial cell motility.  This conclusion may reflect a redundant 
role of JNK for paxillin phosphorylation (Huang et al., 2003).  Moreover, JNK-
dependent leading edge cell protrusions may not be rate limiting (e.g. 
adhesion and rear-end detachment).  JNK may therefore have specific roles 
in the regulation of cell movement rather than a general role in cell motility.   
 
JNK is required for normal mammary gland development 
Transplantation assays demonstrated that JNK is not required for the 
formation of a mammary gland in a virgin female mouse (Figure IV.6).  
However, developmental defects were detected.  Thus, examination of 
terminal end buds (TEBs) at 2 weeks following transplantation demonstrated 
that the lumenal clearance found in control TEBs was incomplete in JNK-
deficient TEBs (Figure IV.6E).  Previous studies have established that 
lumenal clearance is caused by cell death, partially mediated by apoptosis 
(Mailleux et al., 2008), that involves the BH3-only proteins Bim (Mailleux et 
al., 2007; Zhan et al., 2008) and Bmf (Schmelzle et al., 2007).  Interestingly, 
Bim and Bmf are targets of pro-apoptotic signaling by JNK (Hubner et al., 
2008; Hubner et al., 2010).  Loss of JNK signaling may lead to defects in 
Bim/Bmf function and consequently failure of lumenal clearance (Zhan et al., 
2008).  Nevertheless, it should be noted that the defect in TEB lumenal 
clearance caused by JNK-deficiency was partial (Figure IV.6E), suggesting 
the presence of redundant or compensatory mechanisms of lumenal 
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clearance in the JNK-deficient mammary glands.  This type of compensation 
has been noted in studies of Bim-deficient mammary glands (Mailleux et al., 
2007).   
 JNK-deficiency caused altered branching morphogenesis.  
Transplantation assays demonstrated that JNK-deficiency caused increased 
branching of mammary ducts in vivo.  (Figure IV.6B and F).  This effect of 
JNK-deficiency to cause increased branching morphogenesis was also 
observed in FGF2-stimulated organoid cultures in vitro (Figure IV.5).  The 
mechanism that accounts for increased branching morphogenesis is unclear, 
but it is established that this process is regulated by hormones/growth factors 
and by the interaction of the lumenal epithelial cells with basal myoepithelial 
cells and the extracellular matrix (Fata et al., 2004; Sternlicht, 2006).  One 
potential role of JNK is represented by expression of TIMP isoforms that 
inhibit matrix metalloproteases (MMPs).  JNK-deficiency caused decreased 
expression of Timp1/2/3 (Figure IV.6B).  Decreased TIMP activity may lead to 
increased activity of MMP3 and MMP9 that function, in part, to promote 
branching morphogenesis (Lee et al., 2000; Wiseman et al., 2003).  This 
mechanism may contribute to the altered branching morphogenesis caused 
by JNK-deficiency.   
 Together, these data demonstrate that JNK contributes to the normal 
development of the mammary gland in virgin mice.  A goal for future studies 
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will be to test whether JNK-deficiency alters the morphological changes 
associated with pregnancy (lactation and involution).   
 
JNK may play role in mammary tumor development 
The effect of JNK-deficiency to perturb development of the mammary gland 
may be relevant to breast cancer.  JNK may act as a tumor suppressor or as 
an oncogene (Davis, 2000).  Work presented here using deficiency of JNK1 
or JNK2 indicate that loss-of-JNK can increase mammary carcinoma in the 
Trp53 BALB/c mouse model. Moreover, JNK2-deficiency increases breast 
cancer in a transgenic mouse model with expression of polyoma virus T 
antigen (Chen et al., 2010).  Whether compound JNK-deficiency also 
increases mammary carcinoma development is unclear.  However, the 
methods developed during the completion of these studies will enable this 
question to be resolved by analysis of the cohort of mice with mammary 
transplants from KRasG12D/+ Trp53 donor mice that have been created.  It 
should be noted that among the possible outcomes, compound JNK-
deficiency may play no role in mammary carcinoma development in this 
model.  For example, JNK does not appear to play a major role in colitis-
associated colon cancer (Figure IV.S1).  However, JNK does play important 
roles in other types of cancer (Whitmarsh and Davis, 2007).  Since JNK 
represents a potential therapeutic target for treatment of patients with cancer, 
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it is important that the role of JNK in breast cancer is established.  This 
question remains a key goal for future research. 
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Figure IV.1  JNK-deficient mammary epithelial cells.   
A,B)  Jnk1LoxP/LoxP Jnk2-/- CreERT mice treated without or with tamoxifen in vivo 
were used to prepare mammary gland extracts and primary mammary gland 
epithelial cells.  Genomic DNA was examined by PCR to detect Jnk1LoxP and 
Jnk1 alleles (A).  The expression of JNK and -Tubulin was examined by 
immunoblot analysis (B).   
C)  Primary cultures of CreERT (Control) and Jnk1/ Jnk2-/- CreERT mammary 
epithelial cells prepared from tamoxifen-treated mice were examined by 
immunofluorescence analysis by probing with antibodies to pan-cytokeratin 
(red) and E-cadherin (green).  DNA was stained with DAPI (blue).  
Representative images are shown.   
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Figure IV.2  Effect of JNK-deficiency on mammary epithelial cell 
proliferation.   
A)  Primary cultures of CreERT (Control) and Jnk1/ Jnk2-/- CreERT mammary 
epithelial cells prepared from tamoxifen-treated mice were examined by 
phase contrast microscopy. Representative images are shown.   
B)  The cells were pulse-labeled with BrdU and examined by flow cytometry.  
The number of BrdU positive cells (%) is presented (mean ± SD; n = 5).  
Significant differences between Control cells and JNK-deficient cells are 
indicated with an asterisk (P < 0.05).   
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Figure IV.3  Effect of JNK-deficiency on mammary epithelial cell motility 
and invasion.   
A,B)  Primary cultures of CreERT (Control) and Jnk1/ Jnk2-/- CreERT 
mammary epithelial cells prepared from tamoxifen-treated mice were 
examined using Boyden chambers coated with Collagen I (A) or with a 
Matrigel layer (B).  The relative number of cells that moved from the upper 
chamber to the lower chamber is presented (mean ± SD; n = 5).  Significant 
differences between Control cells and JNK-deficient cells are indicated with 
an asterisk (*, P < 0.05;  **, P < 0.001).   
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Figure IV.4  Effect of JNK-deficiency on mammary branching 
morphogenesis.   
A)  Primary organoid CreERT (Control) and Jnk1/ Jnk2-/- CreERT cultures 
prepared from tamoxifen-treated mice were examined by 
immunofluorescence microscopy by staining with an antibody to smooth 
muscle actin (SMA, green) and with phalloidin to stain F-actin (red).  DNA 
was stained with DAPI (blue).  Branching morphogenesis was initiated by 
treatment of the cultures with FGF2.  The organoids were examined using a 
Leica TCS SP2 confocal microscope by acquiring 10 optical sections that 
were collapsed to a single image.   Representative images are shown.   
B)  The number of branches per organoid was measured (mean ± SD, n = 
20).  Significant differences between Control cells and JNK-deficient cells are 
indicated with an asterisk (*, P < 0.01).   
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Figure IV.5  Effect of JNK-deficiency on mammary epithelial cell gene 
expression.   
RNA was isolated from primary cultures of Control (CreERT) and Jnk1/ Jnk2-/- 
CreERT mammary epithelial cells prepared from tamoxifen-treated mice.  The 
expression of mRNA was examined by quantitative RT-PCR.  The mRNA 
measurements were normalized to the amount of Gapdh mRNA detected in 
each sample.  The data presented represent the mean ± SD (n = 5).  
Statistically significant differences between control and JNK-deficient 
mammary epithelial cells are indicated with an asterisk (*, P < 0.05; **, P < 
0.001).   
A)  The expression of Mmp2/3/9/14 and Adam17 mRNA.   
B) The expression of Tim1/2/3, Tgf1, and Spry2 mRNA. 
C) The expression of integrin 1/2/5/6, integrin 1, and Ddr1/2 mRNA. 
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Figure IV.6  Effect of JNK-deficiency on mammary gland development.   
Transplantation assays were performed using mammary tissue from 
tamoxifen-treated female donor mice and female recipient nude mice.  
Control (CreERT) tissue was transplanted in one cleared mammary gland and 
Jnk1/ Jnk2-/- CreERT tissue was transplanted in the contralateral gland of the 
same recipient mouse.   
A-C)  Whole mount mammary glands stained with carmine alum at 8 weeks 
following transplantation are shown (A,C).  The number of branches per unit 
length (mm) of duct is presented as the mean ± SD; n = 3 (B).  Statistically 
significant differences are indicated with an asterisk (*, P < 0.05).  Scale bars: 
5 mm (A); 200 µm (C).   
D-F)  Terminal end buds in whole mount mammary glands stained with 
carmine alum at 2 weeks following transplantation are shown (D).  Sections of 
the end buds in the whole mounts of the glands were stained are presented 
(E).  The number of branches per unit length (mm) of duct is presented as the 
mean ± SD; n = 3 (F).  Statistically significant differences are indicated with 
an asterisk (*, P < 0.05).  Scale bars: 200 µm (D); 100 µm (E). 
 122
 
 
 
 
 123
Figure IV.S1  Effect of JNK-deficiency on the intestinal epithelium.   
A)  BrdU incorporation in the small intestine (S.I.) and colon was examined by 
immunohistochemistry.  No significant differences were detected between 
control mice (Villin-Cre+/-) and JNK-deficient mice (Villin-Cre+/- JnkLoxP/LoxP 
Jnk2-/-).   
B)  S.I. and colonic epithelial cells were isolated and examined by immunoblot 
analysis by probing with antibodies to p53, JNK, and ERK.  The effect of 
exposure of mice to ionizing radiation (800 Rads) prior to euthanasia at 270 
mins post-irradiation.  Control mice (Villin-Cre+/-) and JNK-deficient mice 
(Villin-Cre+/- JnkLoxP/LoxP Jnk2-/-) were compared.   
C)  Colitis-associated colon cancer was examined using the 
azoxymethane/DSS model.  No statistically significant difference in the 
number of colon tumors was detected in control mice (JnkLoxP/LoxP Jnk2-/-) and 
mice lacking JNK in the intestinal epithelium (Villin-Cre+/- JnkLoxP/LoxP Jnk2-/-).  
The data presented represent the mean ± SD (n ≥ 7).   
D)  Sections of control and JNK-deficient colon tumors were examined by 
immunohistochemistry using antibodies to BrdU, phosphoSer63-cJun, and 
JNK.   
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CHAPTER V 
DISCUSSION AND FUTURE DIRECTIONS 
 
The JNK signaling pathway is important for transducing a wide variety of 
external signals that ultimately alter cell behavior. Gene knockout and 
conditional approaches have uncovered a role for JNK in normal cell function 
as well as disease. Although there is evidence that the different JNK isoforms 
have different functions, redundancy still exists, and therefore it is of interest 
to evaluate compound JNK-deficiency. The work presented here examines 
the role of compound JNK-deficiency and single knockouts in the context of in 
vitro cell transformation assays (Chapter I) as well as in vivo models of 
tumorigenesis (Chapter I and Chapter II). Since the cellular pathways 
involved in tumor formation and progression represent aberrant versions of 
normal developmental pathways, I also sought to determine the role of JNK-
deficiency in cell growth, migration, and tissue morphogenesis (Chapter III).   
 
JNK and Ras-initiated Tumor Formation 
The work presented here demonstrates a requirement for JNK in Ras-
mediated cell transformation and lung tumor formation. JNK-deficiency 
suppressed tumor formation in both a xenograft model (Figure II.6) and a 
model of lung tumorigenesis (Figure II.7). Analyses of lung tumor sections 
and tumor lysates show that JNK-deficiency results in decreased tumor cell 
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proliferation (Figure II.7 E and F), suggesting that JNK provides a survival 
signal that is necessary for tumor growth. cJun is a major JNK substrate that 
is required for cell growth, oncogene-mediated transformation and mouse 
models of tumor formation (Johnson et al.,1996; Nateri et al., 2005). 
Therefore, lack of sufficient cJun activity might account for the reduced 
proliferation observed in JNK-deficient tumors. It has also been demonstrated 
that Jnk1-deficient MEF have decreased expression of cyclins (Jaeschke et 
al., 2006), another possible mechanism whereby JNK can mediate cell cycle 
progression. Though some of these observations were made in MEF, it is 
possible that the same mechanisms could contribute to the effects of JNK-
deficiency on lung tumor formation. 
In addition to reduced growth, JNK-deficient MEF showed reduced 
levels of ROS and altered expression of cadherins (Figure II.2 B and Figure 
II.5 B-D), suggesting that JNK promotes transformation and tumor formation 
through additional pathways. The link between increased levels of ROS, 
mutant Ras expression, and cellular transformation is well established 
(Mitsushita et al., 2004; Suh et al., 1999; Kamata and Hirata, 1999). Induction 
of Nox enzyme expression has been shown to result from oncogenic Ras 
expression, and it appears that Nox enzymes can then activate MAPK 
pathways to regulate gene expression (Wu and Terada, 2009). Nox4 
upregulation has specifically been implicated in Ras-mediated transformation 
of fibroblasts (Dolado et al., 2007) and Nox4 is critical for proliferation of 
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malignant human melanoma cell lines (Brar et al., 2002). In the context of the 
work presented in this thesis, JNK signaling is important to maintain 
expression of Nox4 and therefore ROS production. It is possible that JNK 
could regulate transcription of Nox4.  
 Similarly, JNK might function to regulate E-cadherin expression, or 
influence its localization through phosphorylation of -catenin. Activation of 
JNK has been shown to promote disruption of cell-cell contacts via a 
mechanism involving phosphorylation of -catenin complexed with E-cadherin 
(Lee et al., 2009). In epithelial cells, JNK has been shown to contribute to the 
process of epithelial-mesenchymal transition (EMT), characterized by 
changes in cadherin expression. Specifically, the ability of JNK1-null lung 
epithelium to undergo EMT is suppressed (Alcorn et al., 2008). The present 
study provides further evidence of a role for JNK in decreased intercellular 
adhesion, maintenance of cell morphology and promotion of tumor formation.  
 
JNK and Trp53-Mediated Mouse Mammary Cancer 
The work presented here demonstrates a role for JNK1 and JNK2 in the 
development of mammary adenocarcinomas in BALB/c mice heterozygous 
for Trp53. Specifically, in this model both JNK1- and JNK2-deficiency leads to 
reduced tumor-free survival (Figure III.5 and III.6), suggesting that both 
isoforms act to suppress tumor development. JNK1-deficient mice also 
developed more breast tumors than Trp53-/+ mice, although not significantly 
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(Figure III.5 B). There is evidence in support of the tumor suppressive effects 
of individual JNK isoforms on tumor development (Kennedy et al., 2003; Chen 
et al., 2001). More recently, in a transgenic model with polyoma virus T 
antigen expression, JNK2-deficiency was implicated in more rapid 
development and higher incidence of breast tumors (Chen et al., 2010). 
JNK2-deficiency was correlated with increased genomic instability (Chen et 
al., 2010); such a mechanism might similarly be at play in the Trp-/+ model. 
Indeed, evidence exists to support a role for the JNK pathway in the DNA 
repair response to genotoxic agents (Hayakawa et al., 2004; Potapova et al., 
2001). Reduced JNK-mediated apoptosis might also account for the tumor 
suppressive action of JNK-deficiency (Kennedy et al., 2003).  
The results of the present study contrast with previous studies, as well 
as work presented in this thesis, indicating a pro-tumorigenic role for JNK. It is 
possible that tissue-specific differences can account for such contradictions, 
and the possibility remains that compound JNK-deficiency might have 
different effects. Along these lines, I have employed a transplantation 
approach to examine compound JNK-deficiency in a KRas-  and Trp53-
mediated model of mammary tumor development. I generated donor mice 
that express conditional alleles of Trp53, oncogenic Kras, CreERT, and Jnk1 
and are null for Jnk2. In conjunction, I generated control mice expressing 
conditional alleles of Trp53, oncogenic Kras, and CreERT. After transplantation 
into a nude host, administration of tamoxifen activates Cre and induces 
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deletion of the floxed alleles.  I am currently investigating tumor development 
in these mice. 
 
JNK-Deficiency and Mammary Morphogenesis 
This work shows that JNK is important for mammary gland development. 
Several studies in both invertebrate and vertebrate models have shown that 
JNK is required for tissue morphogenesis (Weston et al., 2003, 2004; Kuan et 
al., 1999). Furthermore, JNK has been shown to be required for migration in 
fibroblasts (Jaeschke et al., 2006), for phosphoryation of paxillin and cell 
movements in epithelial cells (Huang et al., 2003), and for formation of the 
leading edge in motile epithelial sheets (Homsy et al., 2006). In contrast, my 
results show that in mammary epithelial cells JNK is not required for 
migration. The fact that elongating mammary ductal cells move coordinately 
without the extension of leading edge cells (Ewald et al., 2008) indicates that 
the underlying process might not involve JNK signaling.  
Although JNK is not required for mammary epithelial cell growth or 
migration (Figure IV.2 and IV.3), JNK does appear to play a role in mammary 
branching morphogenesis in vitro and in vivo (Figure IV.4 and IV.6). I 
observed that JNK-deficiency results in more numerous branches using both 
an in vitro approach (Figure IV.4 B) as well as a transplantation approach 
(Figure IV.6). Several molecules are known to mediate branching in the 
mammary gland, specifically matrix remodeling enzymes (MMPs) and their 
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inhibitors, the TIMPs (Fata et al., 2003). Furthermore, the sheddase ADAM17 
has been shown to be necessary for liberating the EGF receptor ligand 
amphiregulin (Sternlicht et al., 2005). Examination of the expression levels of 
these and other potential regulators of branching morphogenesis 
demonstrated, in particular, significantly decreased expression of TIMPs 
(Figure IV.5 B). A decrease in the expression of TIMPs can serve to enhance 
the activity of MMPs, which can alter branching morphogenesis. MMP3 
overexpression in the mammary gland leads to increased branching in vivo, 
while MMP3-deficient mice show significantly reduced branching (Wiseman et 
al., 2003). Although the authors also examined Timp1-/- mice and found that 
it was not required for branching morphogenesis, they conclude that 
redundancy exists among the major TIMP isoforms in the mammary gland 
(TIMP1, 2 and 3) and that other regulatory enzymes are present as well. JNK 
could therefore function as a positive regulator of TIMP expression in the 
mammary gland.   
 
Conclusions 
This dissertation attempts to determine the effects of compound JNK-
deficiency in cancer development as well as normal tissue morphogenesis. 
Observations with single JNK knockouts revealed some functional 
redundancy, therefore, it has been of interest to examine normal and 
pathological processes in the context of compound JNK-deficiency. To 
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overcome the inability to generate Jnk1-/- Jnk2-/- mice due to embryonic 
lethality, conditional JNK knockout mice have been made and bred with Cre-
recombinase expressing mice. I have determined the importance of JNK-
deficiency for transformation and tumor formation, and I also initiated studies 
to determine the role of JNK in epithelial cells, where previously only MEF 
studies have been conducted. Looking ahead, additional studies might 
include an exploration of how JNK contributes to fundamental aspects of cell 
biology in additional epithelial cell types and branched organs, such as the 
kidney and lung. To extend our knowledge about the JNK pathway in tumor 
development, future work should move towards a mechanistic understanding 
of the actions of JNK to either promote or suppress tumor formation.  
 
Future Directions 
(1) Determine the effect of compound JNK-deficiency in a mouse model of 
breast cancer. 
(2) Examine the effect of compound JNK-deficiency in other epithelial cell 
types.  
(3) Using a tissue-specific approach, determine the effect of compound 
JNK-deficiency in the development of other branched organs, such as 
the lung.  
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